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INTRODUCTION 
                  Cancer is one of the most dreaded  diseases in the world. As the life 
expectancy of the population rises, there is an increasing incidence in the trend 
of cancer in the world (1) . They pose a significant health problem especially in 
developing countries, including India. Due to high exposure to smokeless and 
smoke tobacco among Indian people, head and neck cancers in India continues 
to be a major public health problem and it causes significant morbidity and 
mortality. 
           Head and neck is the most essential structure for physiological functions 
like respiration, nourishment, verbal communication and appearance, which are 
only one of its kind.  Any kind of surgical procedure, reconstruction, radiation 
and chemotherapy induced toxicities has got a lot of difficulties over the normal 
physiological functions; causes disfigurement and decreases the quality of life. 
Head and neck region cancers represent a heterogeneous group of cancers 
arising from the mucosa of upper aerodigestive organs, lined by squamous 
epithelium. It comprises the cancers in the following anatomical regions, 
nasalcavity, nasopharynx, oral cavity, oropharynx, hypopharynx, the larynx, the 
salivary glands and the para nasal sinuses. 
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      The burden of head and neck cancer in the world is large and significant, 
being the 6th most common type of cancer overall. In India the incidence is even 
higher and is one of the most common type of cancer. The incidence also varies 
according to the geographic distribution and the local habits. Its incidence 
highly correlates with the abuse of tobacco in its various forms and the 
synergistic effect of its combination with its partner in crime, alcohol. 
            Majority of the patients present in the locally advanced stage where they 
are treated with a combination of all the three major modalities of oncology- 
surgery, chemotherapy and radiotherapy. However even with the best of therapy 
the overall 5 year survival amongst this group hovers around the 50% mark, and 
it is even less in a developing country like ours. And even with all the recent 
advances in therapeutics in all the three fields there has been no significant 
change in the survival. 
   EPIDEOMOLOGY: 
                          Head and neck cancers in India accounts for about 30% of all 
cancers in the males, constitute 11 to 16% in females. Over 200,000 cases of 
head and neck cancers occur each year in India. Nearly 80,000 oral cancers are 
diagnosed every year in our country . 
According to study published in Lancet in March 2012, the tobacco 
related cancers represented around 42% of male and 18% of female cancer 
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deaths in India. In men two most common fatal cancers are oral (including lip 
and pharynx) and lung (2).  
In Tamilnadu, MMTR states that most common cancer in men is head 
and neck cancer (19.23%) followed next  by stomach cancer(13.98%) and  lung 
cancer (12.46%). In women, breast cancer is the most common (20.87%) 
followed by cervical cancer (11.46%), stomach cancer (8.11%) and head and 
neck cancer (7.53%). 
In our institute Barnard Institute of Radiology & Oncology, head and 
neck cancers constitute the majority of cases registered in our OPD. Majority of 
them are squamous cell carcinomas (~95%) with other histologies making up 
the remaining. Nearly 75% of them present in the locally advanced stage. Only 
around 20 to 25% of the cases present in the early stages. Most of them belong 
to poor socioeconomic status, tobacco users either in smoked form such as 
cigarettes, beedis or non-smoked forms such as pan etc. 
RISK FACTORS: 
TOBACCO: 
                     Among youth,  there is some evidence of cancerous growth in 
use of other forms of tobacco (e.g., cigars, water pipes, electronic cigarettes)  
that may be displacing cigarette use.  
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                     A common index of cancer risk is pack-years, or the number of 
packs of cigarettes smoked per day multiplied by the number of years smoked 
in the lifetime. In general, the higher the number of pack-years, the greater the 
cancer risk (3). The level of tobacco exposure is ultimately driven by use 
behaviors, including the number of cigarettes smoked, the patterns of smoking 
on individual cigarettes, and the number of years smoked. The primary driver of 
smoking behavior is nicotine, the major addictive substance and primary 
reinforcer of continued smoking. Nicotine is metabolized primarily to cotinine, 
which is further metabolized to trans-3â€²-hydroxycotinine (3HC), catalyzed by 
the liver cytochrome P450 2A6 enzyme. The ratio of 3HC to cotinine in plasma 
or saliva can be used as a reliable noninvasive phenotypic marker for CYP2A6 
activity. CYP2A6 activity is known to vary across racial/ethnic groups, with 
those of African or Asian descent showing slower metabolism than those of 
Caucasian descent. In these analyses, the N-nitrosamines, benzene, 1,3-
butadiene, aromatic amines, and cadmium often rank highly. 
SMOKELESS TOBACCO: 
Globally there is a 60% increase in alternative nicotine delivery systems 
like snuff, lozenges(5). Betel quid is extensively used in India. It is also called 
aspan which consists of pieces of areca nut, tobacco and slaked lime. Added to 
this are spices, cardamom, cloves according to the local preferences and are 
varyingly called as gutkha, zarda, mawa, khaini (6). 
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ALCOHOL: 
   Alcohol has synergistic effect with tobacco. Duration, intensity and 
concentration of alcohol consumption directly correlates with oral cavity cancer.  
A meta-analysis from 26 studies of oral and pharyngeal cancers found that 
consumption of  25, 50, or 100 g pure alcohol/day  was associated with a pooled 
relative risk (RR) of 1.75, 2.85, and 6.01, respectively, of oral and pharyngeal 
cancer .Alcohol consumption also leads to immunosuppression, alcohol related 
diseases, altered behavior, unhealthy dietary pattern, and unstable emotional 
balance. All these factors have impact on cancer treatment and survival.  
HUMAN PAPILLOMA VIRUS: 
                HPV infection is proved to be one of the causative factor in SCCHN. 
HPV prevalence is  about 30-35% observed in head and neck cancers, with  
HPV-16 being detected in 60- 90% of infected cancer cases. HPV prevalence 
has been found to be highest in oropharynx tumors (palatine tonsil), less 
common in the oral cavity (7,8). 
The oncogenesis of SCCHN by HPV is by transformation of epithelial cells by 
viral oncoproteins E6 and E7  which inactivate the tumor suppressor genes p53 
and Rb in the host cell leading on to increased cell proliferation and inhibition 
of apoptosis. 
HPV positive oropharyngeal cancers have characteristic features like 
- Young patients, 
- Nonsmokers 
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- Non alcoholics 
- Present with locally advanced disease with large T and N stage 
- Often with basaloid histology  
- Poorly differentiated 
-Sexually transmitted cancer due to oral sexual activity 
- Better prognosis due to sensitivity to radiotherapy and chemotherapy as   
compared HPV negative SCCHN 
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OTHER RISK FACTORS: 
             Diet deficient in antioxidants has been implicated to cause cancer in 
about 10% cases, spicy food consumption, sharp teeth, wood dust, heat fumes, 
heavy metal exposure (like asbestos, nickel, chromium), submucous fibrosis etc 
are also risk factors. 
          Plummer Vinson syndrome due to chronic iron deficiency and its 
association with post cricoid web can produce hypopharyngeal cancer. 
         Chronic actinic exposure can produce cancer of lip. 
 
PRECANCEROUS CONDITIONS: 
Leukoplakia, Erythroplakia, Submucous fibrosis, Lichenplanus, Epidermolysis 
bullosa, Discoid lupus erythematosus etc . 
Leukoplakia: 
A white mucosal patch or plaque, most common premalignant lesion of 
the oral cavity. It resolves with cessation of smoking. 
Erythroplakia: 
Reddish discolouration of the mucosa, 15-20% increased risk of cancer.  
In a study done by Northern Ireland  states that, only 15% of dysplastic 
lesions and 1% of non-dysplastic lesions(epithelial hyperplasia, lupus etc) turn 
to neoplasia (9). 
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INHERITED CONDITIONS like Fanconi Anemia (FA), Ataxia 
Telangiectasia, Blooms Syndrome, & Li-Fraumeni Syndrome has increased risk 
of head and neck cancer. 
                   Inspite of all the aggressive campaign waged against tobacco, the 
rates of tobacco addiction, especially amongst the younger generation is 
increasing and as a result the incidence of tobacco related cancer in general and 
head and neck cancer in particular continues to show an increase. There is also 
an increasing number of cancers in the younger adults reflecting the widespread  
use of tobacco products amongst this group.   
 ANATOMY: 
         The  ORAL CAVITY  includes Mucosal Lip, Buccal Mucosa, 
Alveolar Ridge, Retromolar Trigone, Floor of the Mouth, Hard Palate and Oral 
Tongue 
Lip: The lip begins at the junction of the vermilion border with the skin and 
includes only the vermilion surface. It is well defined into an upper and lower 
lip joined at the angle of mouth. 
Buccal Mucosa: Includes the membranous lining of the inner surface of the 
cheeks and lips from the line of contact of the opposing lips to the line of 
attachment of mucosa of the alveolar ridge (upper and lower) and 
pterygomandibular raphe. 
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Alveolar Ridge: Mucosa overlying the alveolar process of the mandible or 
maxilla which extends from the line of attachment of mucosa in the 
gingivobuccal sulcus. 
Retromolar Trigone: Mucosa overlying the ascending ramus of the mandible 
from the last molar tooth to the apex superiorly, adjacent to the tuberosity of the 
maxilla. 
Floor of the Mouth: Semilunar space overlying the mylohyoid and hyoglossus 
muscles, extending up to the undersurface of the tongue. Its posterior boundary 
is the base of the anterior pillar of the tonsil. The ostia of the submandibular and 
sublingual salivary glands lie in the floor of mouth. 
Hard Palate: Semilunar area between the upper alveolar ridge and the mucous 
membrane covering the palatine process of the maxillary palatine bones. It 
extends from the inner surface of the superior alveolar ridge to the posterior 
edge of the palatine bone. 
Oral Tongue: The portion of the tongue which extends anteriorly from the line 
of circumvallate papillae to the under surface of the tongue at the junction of the 
floor of the mouth. It is divided into the tip, the lateral borders, the dorsum, and 
the undersurface of tongue. 
PHARYNX:  It is divided into Nasopharynx, Oropharynx and Hypopharynx. 
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Oropharynx: This part of pharynx extends from the soft palate to the superior 
surface of the hyoid bone / vallecula. Oropharynx includes base of tongue, 
vallecula, soft palate, uvula, tonsil with anterior and posterior tonsillar pillar, the 
glossotonsillar sulci and posterior pharyngeal walls. 
Hypopharynx: Extends from the superior border of the hyoid bone to the lower 
border of the cricoid cartilage. It includes the pyriform sinuses (right and left), 
the lateral and posterior hypopharyngeal walls, and the postcricoid region. 
The post cricoid area forms the anterior wall of the hypopharynx. It 
extends from the level of the arytenoid cartilages and to the plane of the inferior 
border of the cricoid cartilage. 
The pyriform sinus extends from the pharyngoepiglottic fold to the 
cricopharynx and bounded laterally by the lateral pharyngeal wall, medially by 
aryepiglottic fold and the arytenoid and cricoid cartilages. 
The posterior pharyngeal wall extends from the level of the superior 
surface of the hyoid bone to the inferior of the cricoid cartilage. 
LARYNX:  Composed of several cartilages connected by ligaments and 
muscles. It is divided anatomically into the Supraglottic, Glottic, and Subglottic 
regions. 
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 The Supraglottic larynx consists of the epiglottis, false vocal cords, 
ventricles, aryepiglottic folds, and arytenoids; the arytenoids are cartilages that 
articulate on the cricoid. 
The glottis includes the true vocal cords and the anterior commissure.  
The subglottis is 2 cm long and extends from 5 mm below the free edge 
of the true vocal cords to the upper margin of the first tracheal ring. 
The preepiglottic space is bounded by the epiglottis posteriorly, the 
hyoepiglottic ligament and vallecula superiorly, and the thyroid cartilage and 
thyrohyoid membrane anteriorly and laterally. 
HISTOLOGICAL CLASSIFICATION: 
       Squamous cell carcinoma constitutes 90 - 95% of the head and neck 
cancers. Remaining 5% are adenocarcinoma, verrucous carcinoma, minor 
salivary gland tumors, melanomas, adenoid cystic carcinoma, 
lymphoepitheliomas, and lymphoma (10). 
        With respect to grades of differentiation based on keratinization, squamous 
cell carcinoma as three types; 
Well differentiated - >75% keratinized 
Moderately differentiated -25_50% keratinized 
Poorly differentiated- <25% keratinized. 
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SYMPTOMS:  
                  Most common presenting symptom is ulcer (for ulceroprolifertive 
lesion) followed by  pain, difficulty in swallowing (dysphagia), pain during 
swallowing (odynophagia), difficulty in breathing (dyspnea), change in voice, 
and neck swelling because of lymph nodal involvement. Other generalized 
symptoms are cough, weight loss, loss of appetite may cause further detoriation 
with treatment like concurrent chemoradiation. Nutritional status of the patient 
plays a major role in treatment outcome. 
PROGNOSTIC FACTORS: 
                Most of our patients present with advanced T stage with Lymph node 
involvement in which case single modality treatment is not possible. Even with 
combined modality treatment, local recurrences occur in 40-50% of the patients. 
TUMOR SIZE:  T stage has major prognostic factor, advanced T stage have 
poor prognosis. 
NODAL INVOVLMENT: reduces the survival by 50%. 
TUMOUR SITE: Early Ca Larynx has good prognosis than oral cavity and 
hypopharynx. Other factors like  perineural invasion, postoperative positive 
margins, extra capsular nodal extension, depth of invasion plays a major role. 
MOLECULAR BIOMARKERS: 
EGFR Mutation:   Studies show that 80- 95% of the squamous cell carcinomas 
of the head and neck are associated with overexpression of EGFR receptors . 
Activated EGFR leads to cell proliferation, inhibits apoptosis, affects cell 
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differentiation, increases cell motility, stimulates angiogenesis and is known to 
induce metastasis. This gives a therapeutic target in manipulating receptor 
pathways in cancer cells with targeted agents, monoclonal antibodies, like 
cetuximab as shown benefit in the advanced stages(11). 
 
P53 MUTATION:  
                Most common gene mutation observed in head and neck cancers. 
Associated with worse prognosis because this gene is involved in cell cycle 
regulation and apoptosis. It shows poor response to chemoradiotherapy. 
HEAD AND NECK CANCER TREATMENT OVERVIEW: 
            Head and neck cancer has a multimodality treatment which includes 
Surgery, Chemotherapy,  Radiotherapy and upcoming targeted therapy. The 
main outcome should be locoregional control with function preservation.  
SURGERY: 
       Surgery was the primary modality used in the treatment of head and neck 
cancers. Primary is usually approached through a trans-oral, transcervical or, 
through mandibulectomy. 
NECK NODES: 
 The anatomy of neck node levels should be known before lymph node 
dissection. There are no capillary lymphatics in head and neck epithelium so 
tumor must penetrate lamina propria before lymphatic invasion to occur. Thus 
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the involvement of lymph nodes in head and neck indicate that the tumor is 
locally advanced.  
 The lymph node levels of the neck are divided into seven levels. 
Level I include Ia submental nodes and Ib submandibular nodes. 
Level II upper jugular nodes , Level III middle jugular nodes  
 Level IV lower jugular nodes,  Level V as posterior triangle lymphnodes.  
 Level VI pretracheal nodes, prelaryngeal and paratracheal nodes  
Level VII mediastinal nodes. 
Other regional nodes include 
Suboccipital ,Retropharyngeal, Parapharyngeal, Buccinator (facial) 
Preauricular, Periparotid and intraparotid depending upon the primary site. 
 Lymph node levels drain a particular site in head and neck. So surgery 
can be planned depending on the nodal region involvement. The primary site lip 
drains into Level I nodes with central part to submental nodes and angle of 
mouth to submandibular nodes. In case of oral cavity tumors mainly Level Ib 
submandibular and Level II nodes. Oral tongue as unique lymphatic drainage 
with Level Ib, II _IV; especially in lymphatics of tongue there is crossing over 
and thus bilateral nodal involvement is possible. Also tongue can have direct 
involvement of level IV node without Level Ib,II nodes involvement. 
Oropharynx will cause Level II and III involvement. 
 In case of Nasopharynx retropharyngeal lymph nodes are involved in 
94% of cases or Level II in 90% of the patients. But it can involve Level II –V 
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group of nodes. In case of Hypopharynx bilaterality is common with 
involvement of Level II – IV group of nodes. Other areas like paranasal sinses, 
middle ear, vocal cords have fewer or no lymphatics. 
 
 
 
 
In a classic radical neck dissection, the superficial and deep cervical 
fascia with its enclosed lymph nodes (levels I to V) is removed in continuity 
with the sternocleidomastoid muscle, the omohyoid muscle, the internal and 
external jugular veins, cranial nerve XI, and the submandibular gland. The 
radical neck dissection can be modified to spare certain structures with the 
intent of decreasing morbidity and improving functional outcome without 
compromising disease control.  
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There are three main types of modified radical neck dissections: type 
I—cranial nerve XI is spared; type II—cranial nerve XI and the internal jugular 
vein are spared; type III (functional)—cranial nerve XI, the internal jugular 
vein, and the sternocleidomastoid muscle are spared. Selective neck dissections 
include the resection of lymph node levels that are at greatest risk for nodal 
metastatic spread. Types include the lateral, posterolateral, and supraomohyoid, 
which include resections of lymph node levels II–IV, II–V, and I-III, 
respectively (13). 
A modified or selective neck dissection is recommended for the cN0 neck, for 
selected clinically positive necks (mobile, 1–3 cm lymph nodes), and for 
removing residual disease after RT when there has been excellent regression of 
N2 or N3 disease 
 INOPERABLE: 
                         In a condition when adequate surgical clearance is not 
achievable , tumor spread to inaccessible areas like base of skull, infiltration 
into carotid artery,fixed nodes surgery is not an option.  If the patient’s  general 
condition is poor  surgery is not possible.  Patients completed chemo 
radiotherapy with residual disease may be amenable to Salvage surgery. 
RADIOTHERAPY: 
                                     Radiotherapy can be administered either  Pre 
operatively, Post operatively or it can be definitive treatment with radiation 
alone in early stage tumors. 
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                   In case of postoperative Radiotherapy it should be administered 
after 4-6 weeks of surgery.  Indications are advanced T stage, multiple node 
positivity and perineural or lymphovascular invasion. Post-operative chemo 
radiation is indicated in the case of positive margins and extracapsular   
extension(NCCN). 
                    From 2D RT to 3D conformal RT to Intensity modulated RT, we 
are able to better spare the normal tissues from the deleterious effects of RT 
while at the same time delivering a substantial dose to the tumor. 
                  The fractionation of radiotherapy can be of different types as 
CONVENTIONAL FRACTIONATION: 
                   As definitive modality  dose of 66-74 Gy is recommended to the 
gross disease and 44-64 Gy to the subclinical disease by the( NCCN). In a 
schedule of 2Gy per fraction 5 days a week. 
ALTERED FRACTIONATION: 
Accelerated Radiotherapy: 
Decreases the overall treatment time so that the tumor cells regenerate less 
during the treatment and hence better loco regional control is achieved. 
Pure accelerated radiotherapy: 
There is a decrease in the overall treatment time but no change in the total dose 
or fraction size. 
Hybrid accelerated fractionation: There are three types. 
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Type A: Drastic reduction in overall treatment time and a considerable decrease 
in the total dose. 
Type B: Treatment time is decreased, total dose remains the same with an 
added break in between treatment(67.2 Gy in 42 fractions of  1.6 Gy twice daily 
over 6 weeks, including a 2-week break). 
Type C(Accelerated concomitant boost): Total dose is same; overall 
treatment time is reduced with concomitant boostregimen (72 Gy in 42 fractions 
over 6 weeks, with 1.8 Gy daily for the first 3.6 weeks and 1.8 Gy [large field] 
plus 1.5 Gy [boost field], 6 hours apart, for the last 2.4 weeks). 
Hyper Fractionated Radiotherapy:  Dose of radiation is increased, dose per 
fraction is significantly reduced, the numbers of fractions are increased and 
overalltreatment time is significantly unchanged (81.6 Gy in 68 fractions over 7 
weeks, with 1.2 Gy given twice daily).. 
Hypo fractionated radiotherapy: 
        Here the dose per fraction is increased, the number of fractions is reduced, 
total dose is decreased, and the overall treatment time is significantly reduced. 
This is mainly used for palliative radiotherapy.  In patients who presents with 
very advanced stage, such cases cure is not possible as effort to alleviate the 
symptoms.  
BRACHYTHERAPY: 
          Brachytherapy is another way of therapy where the radiation source is 
kept in close proximity to the tumour. It can be used as a form of boost to the 
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tumour after initial EBRT or it can be used alone in small early stage disease. Its 
advantage is that the dose delivered is highly conformal and there is minimal 
damage to the adjacent normal tissue. 
CHEMOTHERPY:  
               Role of chemotherapy with radiation is proved in various trials. The 
MACHNC trial has proved overall survival benefit of 4% with addition of 
chemotherapy in a patient treated with surgery or radiotherapy. 
Chemotherapy can be administered either as Induction, Concurrent or Adjuvant 
setting. 
INDUCTION CHEMOTHERAPY: 
             It  proved that induction chemotherapy reduces distant metastates but 
no difference in overall survival. 
The neoadjuvant setting has an organ preservation approach in laryngeal 
cancers-the Veterans Affairs trial used chemotherapy in the neo adjuvant setting 
compared to concurrent chemoradiation to achieve organ preservation (15,21) . 
The use of induction chemotherapy using standard doses of cisplatin and 5 FU 
in various trials has shown a response rate of 60 to 90 % including 25 – 30 % 
complete response. It also decreased the incidence of distant metastasis 
probably because of the effect on micro metastasis in the circulation. But it 
failed to demonstrate any improvement in the survival. The recent phase III 
randomised trial DeCIDE trial which uses induction chemotherapy using 
docetaxel, cisplatin and 5FU followed by concurrent chemo radiation also failed 
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to demonstrate any survival benefit from induction chemotherapy compared to 
concurrent chemo radiation(22).  
ADJUVANT CHEMOTHERAPY:   
In case of postoperative setting with positive margins and extracapsular 
extension(NCCN). Adjuvant chemo as a theoretical benefit of eradicating the 
sub clinical disease left behind after chemo radiation, also postulated that it 
sterilizes the micro metastasis present in the circulation and thereby prevent 
distal recurrence rate and improve overall survival rate. The increased 
sensitivity of minimal residual disease to anticancer drugs has been shown by 
cell cycle and growth fraction studies. Unfortunately these theoretical benefits 
are not proved by any randomised control trials and evidence to support the 
routine use of adjuvant chemotherapy is far from definitive. 
CONCURRENT CHEMORADIATION: 
            In the path of concurrent chemo radiation, initially trials was done with 
Bleomycin,  Mitomycin, Cisplatin etc. But as the results of Meta-analysis 
MACHNC has clearly proved that Cisplatin is the drug of choice in concurrent 
chemo radiation. This trial has shown an absolute benefit of 6.5% +1% at the 
end of 5 years in overall survival with concurrent chemo radiation as compared 
to 2 % benefit with Induction Chemotherapy. 
           Thus Cisplatin is used in various trials in different regimens. Cisplatin in 
three weekly or weekly regimens can be used in a way that the Cisplatin 
cumulative dose should be kept equal to or above 210mg. 
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TARGETED THERAPY: 
           As already stated that EGFR receptors is over expressed in 85-90% of 
head and neck cancers. Inhibitors of EGFR like  monoclonal antibody 
Cetuximab was used in many trials. The EXTREME trial  demonstrated that the 
addition of cetuximab to Cisplatin and 5 FU regimens in metastatic and 
recurrent head and neck cancer resulted in an improved overall survival (23).              
The landmark trial by Bonner et al showed that addition of cetuximab 
concurrently to radiotherapy in locally advanced head and neck cancers resulted 
in a significant improvement in loco regional control and median overall 
survival (24). 
OVERCOMING TUMOR HYPOXIA: 
                             Radiotherapy and chemotherapy preferentially kill the 
actively proliferating cells in the oxygenated regions of the tumour. With each 
dose of radiosensitiser chemotherapeutic drug and radiation, the well 
oxygenated cells in the periphery of tumour die. There is a gross fall in the 
interstitial pressure within the tumour causing opening up of previously closed 
capillaries and redirection of blood flow to the hypoxic regions of the tumour. 
 
 PREVENTION OF HEAD AND NECK CANCER: 
          As there is a  concept of Field Cancerization states that the entire upper 
aero digestive tract is subject to subcellular injury by  exposure to carcinogens, 
hence susceptible to cancer formation. Thus a person with malignancy in upper 
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aerodigestive is prone for 20% increased lifetime risk of second primary tumor. 
This may be due to genetic alterations in time. This forms the basis of 
chemoprevention. 
          Many trials with different chemopreventive agents has been tried. Mainly 
with Cis-Retinoic acid; RTOG ( The Radiation Therapy Oncology Group ) trial 
with 13-cis-retinoic acid in a multi-institutional setting, consisting 1400 patients 
with stage I or II cancer were accrued. Unfortunately, this trial was negative and 
did not show any benefit to low dose isotretinoin in the prevention of second 
primary cancers.Other chemo preventive agents being investigated are green tea 
extracts, curcumin extracts, soybeans etc. 
Other methods of prevention will include: 
1. Awareness regarding tobacco products and  regulations controlling the 
sale of tobacco products. 
2. Awareness about sexual practices like oral sex resulting in HPV 
infection. 
3. Abstinence from alcohol 
4.  Good oral hygiene 
           5. Good nutrient rich diet, fresh fruits and vegetables 
RATIONALE OF THIS STUDY: 
This study was based on the DAHANCA 6 .In this study patients were 
treated with 6 fractions per week to a total dose of 66Gy which reduced the 
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overall treatment time by 1week. Withers et al., and Bentzen and Thames 
showed that a dose of 0.48 Gy per day was recovered by tumour during 
fractionated radiotherapy of HNSCC. This was the reason why in our study in 
which overall treatment time was reduced by 1 week, produced higher response 
than conventional fractionation. By reducing overall treatment time by 1 week 
the ‘Dose recovery factor’ of 3.3Gy was avoided. 
         As the MACHNC trials clearly proved the benefit of adding chemotherapy 
concurrently with radiation shows improvement in overall survival of  8% at the 
end of 5yrs.Concurrent chemo radiation forms the treatment of choice in 
Locally Advanced Squamous cell carcinoma of Head and Neck . 
 
 
CISPLATIN: 
  Cis-diaminedichloroplatinum is a platinum analogue that 
covalently binds to DNA analogue with preferential binding to the N-7 position 
of guanine and adenosine and causes the production of crosslinks either 
intrastrand (>90%) or interstrand (<5%) breaks that eventually lead to inhibition 
in DNA synthesis function as well as inhibition of transcription.  It can also 
bind to nuclear cytoplasmic proteins resulting in cytotoxic effects. Apart from 
its cytotoxic effect it also acts as a radiosensitizer for radiation. 
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                    It is given parenterally and is widely distributed in plasma with less 
than 10% remaining in the plasma after 1 hour of infusion. Inside the cells it 
undergoes a reaction where a chloride molecule is replaced by a water molecule 
leading to the production of a highly reactive species which causes the cell 
damage. It is excreted mainly through the kidney. 
The main toxicities of cisplatin include 
 Nephrotoxicity: due to its activity on the renal microtubules, it causes renal 
damage. Dose limiting in upto 35-40% of patients. It is generally reversible 
however the effect is dose related and can lead to acute as well as chronic 
renal failure. 
 Myelosuppresion: it is seen in 25-30% of patients with all the three cell 
lineages equally effected. As the dose is increased, leucopenia and 
thrombocytopenia are more pronounced. 
 Ototoxicity: is also dose related resulting in high frequency hearing loss 
and tinnitus. 
 Neurotoxicity: this is dose related most commonly resulting in in 
peripheral sensory neuropathy. Stocking and glove pattern of paresthesias 
and numbness are classically seen. Motor function defect, enceplhalopathy 
and seizures can also occur. 
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 Nausea and vomiting: it is also a common problem with the use of 
cisplatin. It can occur immediately- acute form or after 24 hours of infusion- 
delayed form.  
 Other toxicities like alopecia, ocular toxicity hypersensitivity, 
azoospermia, sterility etc can also be seen. 
  Cisplatin forms the first line of chemotherapy in a number of 
cancers including head and neck cancer, lung cancer, bladder cancer, ovarian 
and testicular cancer, esophageal cancers, etc. the dose usually ranges from 75-
100 mg/m2 in a three weekly regimen to 30-40mg/m2  with a weekly regimen. 
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                         REVIEW OF LITERATURE  
            As the history of cancer and its treatment emerged in concept from the 
late 19th century, newer techniques and combination of chemotherapy with 
radiation has proved its importance in loco regional control and progression free 
survival. 
BIOLOGICAL BASIS OF  FRACTIONATION: 
From experimental data it was evident that the benefits of fractionation were 
due to four factors, which are known as, 
1. Repair 
2. Reassortment 
3. Repopulation 
4. Reoxygenation  
In general, repair and repopulation will tend to make the tissue more 
resistant wheras reassortment and reoxygenation tend to make it more sensitive. 
Tumor, Early responding tissue and Late responding tissues are having different 
cell kinetics, so they are affected by these 4 factors in different ways.  
The Strandquist plot is the relation between the total dose and overall 
treatment time. The extra dose required to counteract tumor proliferation in a 
fractionated treatment is a sigmoidal function of time. The Ellis NSD system 
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made the important contribution of separating the effects of number of fractions 
and overall time. 
THE LINEAR – QUADRATIC MODEL 
The L.Q model explains that the radiation cell kill has 2 components. The 
initial linear component (D) is due to single track events and quadratic 
component (D²) is due to two track events. (D-dose).  
                             S=exp(-D - D²)  
S is the fraction of cells surviving a dose D.  
This model explains why there are different responses between tumor, 
early responding tissues and late responding tissues; this is due to difference in 
repair capacity or shoulder shape of underlying dose-response curve. The dose 
response curve of late responding tissue is more curved than that of tumour and 
early responding tissue. In terms of linear quadratic relationship between effect 
and dose, this translates into a larger  / ratio for early tissue, tumor tissue than 
for late tissue effects, / ratio is the dose at which linear and quadratic 
components are equal. So, by dividing total number of doses, preferentially 
reduces the late effects. The early responding tissue and tumor tissue, 
particularly, squamous cell carcinoma in head & neck are having a large / 
ratio. It is usual in radiotherapy to compare different fractionation regimens 
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using BIOLOGICAL EFFECTIVE DOSE or equivalent doses (BED). Using 
L.Q. Model, as suggested by Jack Fowler at ASTRO and ESTRO Tutorials,  
 E/  =  (nd) × (1 + d /(α/ß)  
E/  - Biologically Effective Dose   n   - Number of fractions  
            d   - Dose per fraction.  
According to linear quadratic Model, Biological Effective Dose for a 
dose 66Gy, delivered in 5.3 weeks by  6 fractions/week is 72.4Gy and for 70 Gy 
in 5.5 weeks by 6 fractions/ week is 76.8 Gy. 
ALTERED FRACTIONATION: 
It has been well documented that a prolonged treatment time may reduce 
the chance of tumor control, and a substantial number of clinical reports 
indicate that a reduction in overall treatment time may result in improved tumor 
control. 
Conventional fractionation was considered as the best balance between 
tumor kill and normal tissue toxicity. It refers to a radiation dose of 2 Gy per 
fraction, five days a week, up to a total dose of 66-70 Gy. This schedule was the 
first to be tried in the field of Radiotherapy and followed till date.  
 
ACCELERATED  REPOPULATION: 
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                                Treatment with any cytotoxic agent, including radiation, can 
trigger surviving cells (clonogens) in a tumor to divide faster than before. This 
is known as accelerated repopulation. During this time the tumor is overtly 
shrinking and regressing, the surviving clonogen are dividing and increasing in 
number more rapidly than ever.  
                         Withers34 and colleagues surveyed the literature on radiotherapy 
for head and neck and estimated the dose to achieve local control in 50% of 
cases as a function of overall duration of fractionated treatment. The analysis 
suggests that clonogen repopulation in this human cancer accelerated at about 
28 days after the initiation of radiotherapy in a fractionated regime. A dose 
increment of about 0.6 Gy per day is required to compensate for this 
repopulation. Such a dose increment is consistent with a 4-day clonogen 
doubling rate, compared with a median of about 60 days for unperturbed 
growth. 
The conclusion to be drawn from this is that radiotherapy, atleast for head 
and neck cancer, and probably in other instances also, should be started as soon 
after it has begun as practicable. It may be better to delay the initiation of 
treatment than to introduce delays during treatment. If overall treatment time is 
too long, the effectiveness of later dose fractions is compromised, because, the 
surviving clonogens in the tumour have been trigerred in to rapid repopulation.                    
Late effects depend primarily on total dose and dose per fraction; overall 
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treatment time within the usual therapeutic range has little influence. Overall 
treatment time affects both acute effects and tumor control.  It is now well 
documented for head and neck cancer, that, local control is reduced by about 0.4 
-2.5% for each day that overall treatment time is prolonged. 
To overcome these problems altered fractionation schedules have come. 
ALTERED FRACTIONATION IN RADIOTHERAPY:  
               EORTC trial by Horriet et al in 1992 - this trial compared 
conventional fractionation, once daily fractionation of 70 Gy in 35-40 fractions 
in 7-8 weeks, to hyperfractionation of total 80.5 Gy in 70 fractions in 7 weeks 
as 2 fractions of 1.15Gy per day. Patients included were T2-T3 oropharyngeal 
carcinoma, N0, N1 disease. In the final analysis it was found that the local 
control was significantly higher in case of hyperfractionation. Also at 5 years, 
59% of patients had local disease-free in this arm compared to 40% in the 
conventional fractionation arm. This trial showed that the treatment regimen is 
an independent significant prognostic factor for loco regional control which was 
responsible for a trend to an improved survival, without a significant difference 
in late toxicity.  
                    DAHANCA 6 and 7 randomized controlled trial showed the 
benefit of short treatment time with six fractionation per week –due to the 
promising results of this trial, this schedule became the standard of management 
in Denmark. According to this trial the 5-year locoregional control rates were 
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70% vs 60% for the six fraction and five-fraction groups. The primary control 
was good but lymph nodes does not show any added benefit. This trial has 
increased acute toxicity but it was transient(35,36).  
                   RTOG 9003 trial compared hyper fractionation and two forms of 
accelerated fractionation to standard fractionation radiotherapy. The 
hyperfractionation arm delivered 1. 2 Gy/fraction, twice daily, 5 days/week to 
81.6 Gy/68 fractions/7 weeks; the accelerated fractionation included split at 1.6 
Gy/fraction, twice daily, 5 days/week, to 67.2 Gy/42 fractions/6 weeks 
including a 2-week rest after 38.4 Gy and another form of acceleration with 
concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day 
to a boost field as a second treatment daily for the last 12 treatment days to 
72Gy/42 fractions/6 weeks. Hyperfractionation and accelerated fractionation 
with concomitant boost showed significantly better local-regional control than 
standard fractionation(16) . 
                    Although Hyper fractionation improves loco regional control, this 
occurs at the cost of increased acute toxicity which results in treatment breaks 
and increased hospital stay. 
Sequencing Chemotherapy with Radiation:  
                 The radiobiological basis of combining Chemotherapy with 
Radiation  is to obtain maximum therapeutic benefit. Tumor cells have 
accelerated cell proliferation, hypoxia and acidity which are not present in 
normal cells. Similarly assessment of various mechanisms of resistance to 
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radiation and different chemotherapeutic agents are also important to be 
considered. 
Spatial cooperation: in this case radiation acts loco regionally and chemotherapy 
at a distant site, without any overlap.  
Independent toxicity: the chemotherapy drugs given may have a different 
toxicity profile and it does not increase radiation reactions.  
Enhancement of tumor response: in this case the ability of chemotherapy to 
enhance the radiation response is exploited. This results in better tumor kill 
based on additive action. This however, does not include the cytotoxic action of 
the drug itself but only its radio sensitizing property, to prevent excess normal 
tissue toxicity. 
If the overall cell killing in the combination treatment is contributed by 
individual cytotoxicity of the drug and individual effect of the radiation, then it 
is called additive effect.  
If the cell killing in combined modality is greater than the cell killing by 
individual cytotoxic agents, then it is called as supra additive effect. This is 
possible when chemotherapeutic agents interact with radiation and potentiates 
the effect of later. 
Inhibition of tumor repopulation:   only in case of concomitant 
Chemoradiotherapy.  
Protection of normal tissue: through administration of agents which selectively 
prevent normal tissue damage. 
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Improved tumor oxygenation: because of increased cell kill, leading to better 
local control. 
     There are numerous trials describing the time of Chemotherapy introduction 
with Radiation. 
Induction chemotherapy: 
           The Department of Veterans Affairs Laryngeal Cancer study 
Group conducted a prospective randomised control study in locally advanced 
laryngeal cancer. The aim of this study was to compare the option of induction 
chemotherapy followed by radiotherapy with surgery reserved for residual or 
recurrent lesions is a feasible alternative to surgery followed by postoperative 
radiotherapy. Patients in the control arm received three cycles of induction 
chemotherapy using cisplatin and 5 fluorouracil. The patients were assessed 
after two cycles of chemotherapy. Any patient who failed to attain at least a 
partial response was taken up for immediate surgery followed by radiotherapy. 
Responding patients were allowed to complete three cycles of chemotherapy 
followed by definitive radiotherapy.  
                 The results of the trial showed that overall survival was same in both 
arms. The 3 year survival rate was 53%. The loco regional recurrences were 
greater in the control arm (12% vs 2%), but since salvage surgery was done in 
recurrent cases the overall survival was not compromised. Another interesting 
result is distant relapses were decreased in the chemo arm (11 % vs 17 %). But 
despite decrease in distant relapses overall survival could not be improved. 64% 
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of the patients recruited in the chemotherapy arm retained functional larynx. 
The authors concluded that in view of the high rate of local recurrences in  
chemotherapy arm, more effective local therapy is needed to achieve larynx 
preservation(21).  
 EORTC/TAX 323 (Vermorken et al. 2007) in this study 358 patients 
with unresectable stage III–IV head and neck cancer were randomized toTPF 
(docetaxol/cisplatin/5-FU) vs. PF (cisplatin/5-FU) induction chemotherapy 
followed by RT alone, delivered with conventional(66 Gy) or hyperfractionated 
(74 Gy) RT. Induction TPF increased median survival (14.5→18.8 months), but 
increased hematological toxicity and chemo-related death (2.3 vs. 5.5%). 10 -
15% of patients after induction chemotherapy were unfit to receive Radiation in 
this study(25). 
         Thus role of Induction chemotherapy followed by Radiation is acceptable 
only in selected patients prone for distant recurrences. This benefit can be 
achieved with the compensation of loco regional recurrence. 
ADJUVANT CHEMOTHERAPY: 
           Adjuvant chemotherapy in Head and Neck following surgery is less 
studied. 
Intergroup study 0034 used postoperative cases were randomized in into 
two arms. Study arm had  3 days of Cisplatin (100mg/m2), 21 day cycle and 
infusional 5 fluorouracil(1000mg/m2/day for 5 days, followed by radiation dose 
of 50-60 Gy Vs control arm had radiation alone without chemotherapy. There 
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was no improvement in overall survival or locoregional control but the 
incidence of distant metastasis decreased significantly from 30% to 20%.  
RTOG 95–01(Cooper et al. 2004): 459 patients with operable cancer of 
the oral cavity, oropharynx, larynx, or hypopharynx who had 2 involved lymph 
nodes, nodal extracapsular extension, or positive margin randomized to post-op 
RT (60–66Gy) vs post-op chemo-RT (60–66 Gy and cisplatin ×3cycles). 
Chemo-RT improved 2-year Disease Free Survival (43→54%), Loco Regional 
Control (72→82%), and had a trend for improved OS (57→63%), but increased 
grade 3–4 toxicity (34→77%). (28) 
EORTC 22931(Bernier et al. 2004): 334 patients with operable 
stage III/IV oral cavity, oropharynx, larynx, and hypopharynx cancer 
randomized to post-op RT (66 Gy) vs. post-op chemo-RT (66 Gy and cisplatin 
100 mg/m2 on days 1, 22, 43). Allpatients received 54 Gy to the low-risk neck. 
Chemo-RT improved 3/5-year Disease Free Survival (41/36→59/47%), 
3/5-year Overall Survival (49/40→65/53%), and 5-year Loco Regional Control 
(69→82%), but increased grade 3–4 toxicity (21→41%)(27). 
Trials conducted by EORTC and RTOG, both showed post-operative 
chemo radiotherapy as improved Disease free survival and loco regional control 
but with increased grade 3&4 toxicity. 
CONCURRENT CHEMORADIATION: 
 Concurrent chemoradiation in locally advanced head and neck cancer, the 
history tracks down to the era when Inj. Mitomycin, Inj.Bleomycin were used 
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with Radiation. Initial trials done by NCOG, EORTC showed improvement in 
loco regional control and overall survival. Also there are trials with single agent 
Inj.methotrexate shows improve in loco regional control. 
.  
But with more understanding of the tumor radiobiology, radiosensitizers 
like 5- Fluorouracil and Cisplatin , either alone or together, have been tried in 
many studies and proved as effective & potent chemotherapy drugs to combine 
with radiation. 
 
META-ANALYSIS OF CHEMOTHERAPY IN HEAD AND NECK 
CANCER (MACH-NC):  
            The first part of this landmark meta-analysis which was published in the 
year 2000 by Pignon et al. This analysis included 63 randomized trials. The 
initial report from 1965-1993, showed a significant absolute overall survival 
benefit of 4%, both at 2 and 5 years (p<0·0001) in favour of chemotherapy.  
Concomitant chemotherapy showed an absolute survival benefit at 2 and 
5 years of 8%. In adjuvant and neoadjuvant setting, there was no significant 
effect of chemotherapy seen on survival. The effect of multiagent concomitant 
chemotherapy was significantly greater than single-agent chemotherapy (hazard 
ratio 0·69 vs 0·87,p<0.01). For the effect of chemotherapy on survival by 
covariate values, the only significant observation was a decreasing effect of 
chemotherapy on survival with increasing age (trend test, p=0·05).As far as 
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timing of chemotherapy is concerned, there was a non-significant decrease in 
risk of death in the concomitant chemotherapy group. This meta-analysis 
included trials which were very heterogeneous and no solid conclusion could be 
drawn regarding the routine use of chemotherapy and the regimen to be used 
(17,18). 
However, the update of this analysis, published in 2009 which included 
93 randomized trials and demonstrated an overall absolute benefit of 
chemotherapy to be 6.5% at 5 years and the hazard ratio was 0.81 (p < 0.0001). 
Whereas  the absolute benefit of Induction Chemotherapy at 5yrs was 2.4% and 
that of Adjuvant Chemotherapy -1.0+ 2.2 % .This absolute benefit in the meta 
analysis proves that Concomitant Chemotherapy has superior results and shows 
advantage over induction or adjuvant chemotherapy. 
There was no significant difference in the benefit of chemotherapy on 
survival (p = 0.14) between postoperative or curative radiotherapy with 
conventional or altered fractionation. Mono and poly-chemotherapy did not 
differ but the effect of chemotherapy was significantly higher (p = 0.006) with 
platinum than with other types of mono-chemotherapy agents. There was only 
one negative “cisplatin alone” trial in this meta-analysis which used a 
cumulative dose of 140 mg/m2 suggesting that the total dose of Cisplatin should 
be considered. It was also demonstrated that there is a statistically significant 
decreasing effect of chemotherapy on survival with increasing age. 
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 This Meta-Analysis clearly states the benefit of concurrent Chemo 
radiotherapy in the Head and Neck Cancer beyond  any doubt. 
Latest trial Concurrent Vs Induction Chemo: 
The DeCIDE (22), a phase III randomised trial using induction 
chemotherapy with Docetaxel, 5 fluorouracil and cisplatin in N2/N3 locally 
advanced head and neck cancers (2012 ASCO meeting). Patients were 
randomised to chemo radiation alone with five days of docetaxel 25 mg/m2, 5 
fluorouracil 600 mg/m2 and hydroxyl urea 500 mg bid concurrently with 
radiation 150 cGy bid or with  two cycles of induction chemotherapy using 
docetaxel 75 mg/m2, cisplatin 75 mg/m2 and 5 fluorouracil 750 mg/m2 for 5 
days followed by the same chemo radiation. 280 patients were recruited to the 
study from 2004 to 2009 and the minimum follow up was two years. The 
primary end point was overall survival. From 142 patients randomized to 
induction, 91% received 2 cycles and 87% continued to chemoradiation. Grade 
3-4 leukopenia and neutropenia rates were significantly higher in IC (p=0.002 
and p=0.02). The authors demonstrated that induction chemotherapy was 
associated with lower distant failure (DF) rates but an improvement in overall 
survival (OS) could not been validated. This was a negative study, as there was 
no overall survival difference with trends favoring the experimental arm in 
terms of disease-free survival. 
Another trial in ASCO 2012 PARADIGM trial (29) Induction 
chemotherapy followed by concurrent chemoradiotherapy (sequential 
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chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally 
advanced head and neck cancer : a randomised phase 3 trial-this study was 
conducted between 2004 to 2008, with a median follow up of 49 months 3-year 
overall survival was 73% in the induction therapy followed by chemoradiation 
group and 78%in the chemoradiation alone group (hazard ratio 1·09, p=0·77). 
Also, more patients had febrile neutropenia in the induction chemotherapy 
.Although survival results were shown to be good in both groups, there was no 
difference between those treated with induction chemotherapy followed by 
chemoradiation and those who received chemoradiation alone.  
Both the DeCIDE and PARADIGM trial did not show a significant 
survival benefit with induction chemotherapy, but the toxicity were high in the 
induction arm. The option of induction Chemotherapy followed  by 
chemoradiation still can be considered in selected patients. 
PLATINUM BASED CHEMORADIATION: 
 Concurrent chemoradiation with cisplatin as become the standard of care 
with the standard land mark trials. Cisplatin acts as a radiosensitizer increases 
efficacy of radiation even at low doses. 
 
WEEKLY CISPLATIN Vs THREE WEEKLY CISPLATIN: 
Due to the benefit and effectiveness of Inj.Cisplatin concurrently with 
radiation in Squamous cell carcinoma of the Head and neck , it is used widely in 
the dose of 100mg/m2 day 1,22,43 regimen. This regimen has become the 
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standard following many trials. But there are trials with smaller doses of 
Cisplatin which has proved to be quite effective. These nonstandard Cisplatin 
schedules have been preferred due to two main reasons – firstly, more frequent 
dosing may provide more radiosensitization during long course of radiation, and 
secondly, a smaller drug dose may have lesser chemotherapy related toxicity 
(32,33,34). With the three weekly regimen it was found that compliance to the 
schedule became a major issue, which is avoided in the case of  smaller weekly 
doses. Based on trials like the Intergroup and RTOG – 0129, it has been 
suggested that the cumulative threshold dose of Cisplatin to achieve maximal 
benefit is 200 mg/m2. Also, as discussed in the MACH-NC analysis, a dose 
below 140 mg/m2 was found to have inferior results. 
WEEKLY CISPLATIN TRIALS: 
 A study published from TATA Memorial Hospital, Mumbai, by 
TejpalGupta in 2009 (30), compared high dose concurrent Cisplatin with 
weekly Cisplatin in a dose of 30 mg/m2 with radiation dose of 70Gy. Planned 
was seven cycles of weekly Cisplatin, two-thirds (65%) of patients in the study 
received ≥85% of planned Cisplatin dose. With a mean follow-up of 19 months, 
the 5-year local control was 57%, loco-regional control was 46% and the 
disease free survival was 43% respectively. Grade 3 or higher acute mucositis 
was seen in 29% cases and dermatitis in 35% cases respectively. This 
essentially manifested in patients receiving radiation dose ≥66 Gy and 6 or more 
cycles of chemotherapy.The conclusion drawn from the study was weekly 
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cisplatin has moderate efficacy with acceptable toxicity with the potential to 
become an optimal chemotherapeutic regimen especially in a limited resource 
setting . 
 Another study published by Homma et al in 2011, including 53 patients 
with locally advanced squamous cell carcinoma used weekly cisplatin 40 mg/m2 
on 7 weeks along with radiation of 70 Gy/2Gy per fraction in 35 fractions. The 
overall survival rate was 93.7% and disease free survival was 88%. The toxicity 
was manageable in all patients. The study demonstrated complete response rate 
of 98.1% This study showed that weekly cisplatin is a feasible alternative with 
less toxicity without compromising the results. Major benefit is that the patients 
can be monitored frequently and dose adjustments can be made if required (31).  
Ho and his colleagues in 2008 showed that most of the patients in 
weekly Cisplatin arm received a higher cumulative dose of 240 mg/m2 or more 
as compared to the 3-weekly Cisplatin arm (p = 0.04). They also found that the 
3-weekly regimen was associated with more delays (41% vs 29%) and 
omissions of chemotherapy (17.4% vs 5.6%) causing lesser patients to achieve a 
less cumulative cisplatin dose, potentially lowering dose-intensity(32). 
A similar study was conducted at the University of Florida, presented at 
the ASTRO 2009 meet, later published in Cancer J 2010. This study 
demonstrated that weekly Cisplatin 30 mg/m2 decreases the treatment toxicity 
without sacrificing efficacy in patients treated with concomitant chemo-
radiation for locally advanced squamous cell carcinoma of the head and neck. 
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79% patients in the study were able to complete at least 6 cycles of 
chemotherapy and 95% patients received RT up to at least 72 Gy. The 5-year 
actuarial outcomes in this study were as follows: Loco regional control rate of 
79%; Distant metastases, 12%; and overall survival of 59%. It was claimed by 
the authors that the toxicity rates of the study were lower than those reported for 
RTOG 9914 and 0129 (33). 
At University of Wisconsin, Tray nor et al studied the feasibility of 
weekly cisplatin with Intensity modulated Radiotherapy (IMRT) in locally 
advanced squamous cell carcinomas.This study was conducted during a period 
of November 2001 to May 2007. A total of 57 patients were included and a 
weekly cisplatin dose of 30 mg/ m2 was used. The prescription dose to the GTV 
was 70 Gy.. The loco regional control was 85.5 % and median overall survival 
was 86.9%. The conclusion drawn from the study was weekly cisplatin 30 
mg/m2 along with IMRT with a GTV dose of 70 Gy is well tolerated (34). 
LOW DOSE DAILY CISPLATIN TRIALS: 
Brainslav Jeremic et al-  dept of otorhinolaryngology studied 
hyperfractionated radiotherapy with or without low dose  cisplatin in advanced  
head and neck cancer. Hyperfractionation was given as 77 GY in 70 fractions 
over 7 weeks with or without low dose daily cisplatin 6 mg/m2 was given for 
five week daily . Patients with chemo radiation arm shows higher survival rates 
than radiation alone arm. Survival rate at 2 years were 68% vs 49%, survival 
rate at 5 years were 46%  vs 25%. Locoregional progression free survival was 
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also high  at 5 years which was 46 % vs 25 %. Distant metastasis free survival 
was also good at 5  years  86% vs 57 %  respectively(39,40). 
A randomised phase 2 trial   Bartelink et al studied about conventional 
chemoradiation with low dose daily cisplatin 6 mg/m2 with 70 Gy RT  in 2 GY 
per fraction over 7 weeks versus modified fractionated schedule giving  3 
fractions / day of 1.6 GY each in weeks of 1,4,7. Both arm shows similar tumor 
response and also shows similar toxicities as that of conventional arm (38). 
H.A.Wolff et al studied the toxicity of low dose daily cisplatin 6 mg/m2  
inpost op patients of locally advanced head and neck cancers. Radiotherapy was 
conventionally given 70 GY of 2 GY  each.3 year OS and locoregional control 
were  67%  and 78% respectively.Grade 3 acute  and chronic toxicities were 
less observed (41). 
P.K.Gupta et al studied the comparison of low dose daily cisplatin 
6mg/m2 with weekly cisplatin along with accelerated radiotherapy in locally 
advanced head and neck cancers. In this study ,low dose cisplatin was given on 
OP basis in 50 ml NS as bolus with 500ml NS prior hydration. Overall survival 
and disease free survival was somewhat  superior  than weekly schedule with 
insignificant P value. Toxicities  like mucositis, dermatitis observed were less in 
low dose arm than in weekly arm(43). 
 
 
 
Aims and Objectives 
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AIM & OBJECTIVES 
The aim of this study was to evaluate and compare the use of  daily low 
dose cisplatin  versus  weekly Cisplatin concurrently with accelerated  radiation 
in locally advanced squamous cell carcinoma of head and neck. 
Primary Objective:  
 To assess and compare  the immediate loco regional response rates in 
locally advanced squamous cell carcinomas of the head and neck treated with 
low dose daily cisplatin  versus  weekly cisplatin concurrently with accelerated 
radiation. 
Secondary Objective:  
 To assess and compare  the acute toxicity to the treatment concurrent 
chemoradiation with low dose daily cisplatin  versus  weekly cisplatin.           
  
Materials and methods 
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MATERIALS AND METHODS 
 STUDY DESIGN: 
                                Double  arm prospective study with a Phase II design. 
STUDY DURATION:    October 2016– August, 2017 
STUDY CENTRE:         Department of Radiotherapy, Barnard Institute of       
Radiology & Oncology, Madras Medical college, Chennai. 
SAMPLE SIZE:            30 consecutive patients in each arm with 
histopathologically proven squamous cell carcinoma of head and neck who 
fulfilled the inclusion criteria were recruited in the study from the outpatient 
department.  
The intent of treatment was to be radical, aiming for cure, considering their 
disease stage, co- morbidities and performance status. 
ETHICAL COMMITTEE APPROVAL: Approval from the institute ethical 
committee was obtained on 04.10.2016. 
INFORMED PATIENT CONSENT:  
All patients enrolled in the study were informed about the merits and 
demerits of participating in this study and signed an informed consent form in 
their regional language, which is Tamil. 
 INCLUSION CRITERIA: 
 Biopsy proven newly diagnosed squamous cell carcinoma of the head 
&neck. 
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 Primary tumor sites: oral cavity, oropharynx, hypopharynx, larynx. 
 
 Age 20- 60 years 
 
 Stage III or IV A locally advanced squamous cell carcinoma 
 
 Previously not exposed to any chemo or radiotherapy 
 
 ECOG 0-1 
 
 No major life threatening comorbidities. 
EXCLUSION CRITERIA: 
 
  Non Squamous Histopathology 
 
 Tumors of nasal cavity, paranasal sinuses  and nasopharynx. 
 
 Inadequate hepatic and renal functions, bone marrow reserve. 
 
  Patient not consenting to chemotherapy at any point in the treatment. 
 
  Previously received treatment for any other malignancy. 
 
  Metastatic or recurrent disease. 
PRE TREATMENT WORK UP: 
1. Detailed history elucidation. 
2. Complete physical examination by inspection, palpation. 
3. Upper aerodigestive tract evaluation by direct and indirect laryngoscopy, 
anterior and posterior rhinoscopy and endoscopy if indicated to know the extent 
of disease and rule out a second primary. 
4. Biopsy from the primary tumor or fine needle aspiration cytology from the 
metastatic lymph node. 
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5. Blood grouping and typing. 
6. Complete blood count. 
7. Renal function test. 
8. Liver function test. 
9. CT scan of the head and neck, plain and contrast, before initiating treatment 
and also after treatment for response assessment. 
10. Chest X ray postero-anterior view.  
11. Cardiac evaluation and fitness.  
12. Naso-gastric tube insertion if indicated  
13. Dental prophylaxis including scaling, dental filling and extraction if 
required.  
14. Tumor stage, performance status and weight were recorded. 
Staging was done based on American Joint Committee staging manual 7th 
edition (for head and neck cancers). 
15. Weekly CBC, RFT, LFT before each cycle of chemotherapy. 
PATIENT PREPARATION DURING TREATMENT: 
All patients enrolled in the study were distributed pamphlets describing in 
brief the do’s and don’ts while on treatment and later.  
Quitting alcohol and tobacco  
The harmful effects of tobacco, both in smoking and nonsmoking form, 
and alcohol were explained to the patient and their addictions as inferior 
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outcome after treatment and also has increased risk of second malignancy due to 
field cancerization effect. 
Dental health: 
Chemoradiotherapy to oral cavity poses an increased risk of dental caries. 
As the production of saliva is altered both in quality and quantity by concurrent 
chemoradiotherapy which leads to alteration of normal flora. Thus causes 
increased risk of caries formation due to mucositis and dryness. Oral discomfort 
due to mucositis can lead to decrease in brushing and flossing, also increases the 
risk of dental caries, which may lead to extraction, soft tissue necrosis, bone 
exposure, and osteoradionecrosis. 
 
Dental care  
Prior to irradiation all patients underwent dental evaluation; scaling and 
filling. Nonsalvageable teeth were extracted prior to radiotherapy to reduce the 
risk of osteoradionecrosis. A gap of two weeks was given after dental 
prophylaxis for proper healing of gums. Prophylactic antibiotic treatment was 
started following extractions if necessary.     
Edentulous patients were evaluated for their oral hygiene any retained root 
tips.Patients were advised not to wear dentures until the mucosa is healed from 
the effects of radiotherapy.Patients were advised to use soft brush and fluoride 
containing toothpaste daily during and after radiotherapy. 
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Mucositis 
The major side effect of chemoradiotherapy is mucositis, a condition 
where patient perceives pain due to inflammation and ulceration of the mucosa. 
It occurs mainly due to disruption of normal mucosal barrier by 
chemoradiotherapy causes production of Reactive Oxygen Species resulting in 
increased production of proinflammatory cytokines (IL-1β, IL-6) which causes 
tissue injury and apoptosis of cells in the mucosa. 
Retrospective review of over 200 head and neck cancer patients treated 
with radiotherapy at MD Anderson cancer centre, 66% of the patients had either 
grade 3 or 4 mucositis. According to various studies patients with oral 
cavity,nasopharynx, oropharynx cancer treated with concurrent chemotherapy 
or altered fractionation radiotherapy, had a higher rate of mucositis producing 
intense pain, weight loss, and treatment breaks which compromises loco 
regional control.  
 Studies shown that daily dose, cumulative dose and volume of irradiated 
tissue determine the severity of mucositis. This pain produced by mucositis can 
lead to nutrition compromise thereby lack of proper hydration and oral hygiene. 
The desquamated epithelium, fibrin, and polymorphonuclear leukocytes in a 
moist background provide a favorable environment for opportunistic infections 
such as candidiasis.  
Thus in this study patient were suggested following oral measures to 
improve their oral hygiene during radiation. 
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- Patient’s oral health were monitored daily during treatment. 
- All patients were advised to gargle 20 to 25 mL of indigenously prepared 
mouthwash by dissolving three tablespoons of soda bicarbonate and three 
tablespoons of table salt (sodium chloride) in 200ml of distilled water, for 
every 4 to 6 hours.  
- Patients who developed mucositis were managed in addition with 
antibiotics and low dose corticosteroids. Oral candidiasis was treated with 
tablet Fluconazole 150 mg per oral for 7 days. 
Other precaution: 
Patients advised to restrain coarse and hot food items as they serve as 
irritant and exacerbate mucositis. 
Oral physiotherapy - in the form of mouth stretching and mouth opening        
exercise also advised to patients to avoid trismus. 
NUTRITIONAL CARE: 
Most of the Head and neck cancer patients suffer from dysphagia and 
odynophagia either because of the tumor or due to treatment related effects like 
mucositis. This can affect the quality of life results in decreased food intake and 
they become nutritionally deprived resulting in weight loss. 
All patients enrolled in this study were given dietary advice and 
encouraged to take easily available, nutritionally rich local foods, dairy products 
and fresh fruits and juices (avoid citrus fruits, acidic and spicy foods). Everyone 
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encouraged to take supplemental calories before treatment daily two raw eggs 
and milk. 
Homemade preparation of health mix  with  milk which is rich in protein 
to regenerate tissue protein. Small soft meals  in the form of bland diet at room 
temperature. All patients were monitored for weight loss every week and special 
meals were designed for individual patients. 
Mostly during third or fourth week of radiation patients develop severe 
mucositis and need supplementary nutrition. Parenteral nutrition was also given 
if needed.Those patients who developed grade 3 or 4 dysphagia were inserted a 
naso-gastric tube so that nutrition was not compromised.  
Before initiation of treatment, it was made sure that all patients had 
normal blood, renal and liver function tests and everyone as given written 
consent for the treatment. 
TREATMENT PROTOCOL: 
  60 locally advanced head and neck cancer patients were selected 
consecutively from the outpatient department, who then underwent the pre 
treatment work up as mentioned before. Following that they were randomized to 
treatment arm 1- low dose daily cisplatin 6 mg/m2 with accelerated radiation 
and treatment arm 2- weekly cisplatin 40 mg/m2 with accelerated radiation . 
RADIATION THERAPY:  
All patients were treated with a accelerated dose schedule of 2 Gy per 
fraction  six days per week with a Theratron Phoenix Tele Cobalt-60 machine.  
52 
 
Patient Position:  
                Patients were made to lie in the supine position with neck slightly 
extended.  
Patient Immobilization:  
Strict immobilization was practiced while irradiating the patient.  
Radiation Portals:  
Patients were treated with opposing lateral radiation portals. 
Verification:  
X-ray simulation was done with the patient in treatment position to verify 
the treatment field.  
Radiation Dose:  
Patients were treated with a dose of 2 Gy per fraction, with 6 fractions per 
week. 
 
    Phase I to include the primary and the draining lymph node regions and 
 
a dose of 44 Gy / 22 fractions / 4.5 weeks was delivered 5 days in a week at 
 
2 Gy / fraction (Monday to Friday). 
 
In phase II-off-cord reduction was done, and a dose of 16 Gy/8 
 
Fractions / 1.5 weeks at 2 Gy / fraction was delivered 5 days in a week 
 
(Monday to Friday). 
 
Phase III will be delivered as a boost on all Saturdays, as limited 
volume 
 
portal including original GTV with a margin of 2 cm. A dose of 10 
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Gy / five fractions / over five Saturdays at 2 Gy / fraction was delivered. 
Radiotherapy was given same in both arms. 
 
CHEMOTHERAPY SCHEDULE:  
Arm 1-low dose  daily cisplatin 6 mg/m2: 
 
     CDDP was  given at 6 mg/m2 (capped at 10 mg) in 50 ml normal 
saline (NS) solution infused  over ten minutes on all radiation treatment days  
after hydration with 500 ml of normal saline. Injection ondansetron 8 mg as 
antiemetics was given just before chemotherapy. This was given on all RT days 
one hour before   radiation .  Renal and hematologic parameters were assessed 
every week. Daily chemotherapy was given on outpatient basis. 
Arm 2-weekly cisplatin 40 mg/m2:    
 Inj.Cisplatin 40mg/m2 diluted in 500 ml normal saline, infused over 2 
hours, every week on Mondays, during radiation to a total of 5-6 cycles. Renal 
and hematologic parameters were assessed prior to each cycle of chemotherapy. 
PREMEDICATION: ARM 2: 
All patients were pre hydrated with one pint of normal saline over one 
hour before starting chemotherapy.  
Premedication given 30 minutes prior to chemotherapy included the following:  
 Inj. Ondansetron 8 mg IV.  
 Inj. Dexamethasone 8mg IV.  
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 Inj. Ranitidine 50 mg IV.  
 Inj. Chlorpheniramine 1 vial.  
All the above mentioned premedication was given on a bid basis. 
Injection Cisplatin 40mg/m2 mixed in 500 ml of normal saline and infused at 40 
drops per minute in about 2 hours. Following this 500ml of normal saline was 
infused again over an hour. 
Blood investigations were repeated every week before chemotherapy and 
hemoglobin < 10g% was corrected by blood transfusion. Colony stimulating 
factor was given when the Absolute Neutrophil Count fell below 1000 
cells/cubic millimeter. Symptomatic thrombocytopenia was corrected by 
platelet transfusion. 
ASSESSMENT DURING CHEMORADIATION:  
Toxicity Assessment:  
Patients were reviewed every day before radiation for any acute toxic reactions 
and infections. Reactions like skin desquamation, mucositis, laryngitis, 
dysphagia etc. were recorded and graded based on RTOG acute radiation 
morbidity criteria. If a patient developed grade 3 or higher reactions 
chemoradiation was suspended. Careful attention was given for maintenance of 
hydration, adequate dietary intake and good oral hygiene.  
 Hematological and renal parameters were assessed on a weekly basis .  
Hb less than 10 mg/dl was corrected by packed red cell transfusion. WBC and 
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platelet counts were kept under regular monitoring. If renal parameters are 
raised adequate hydration was done and nephrologist opinion obtained. 
RESPONSE EVALUATION:  
All patients were reassessed by clinical examination and with a CT Neck, 
4 -6 weeks after completion of concurrent chemo radiation.  
Response to treatment was described based on the Response Evaluation Criteria 
in Solid Tumors (RECIST 1.1 version) Criteria. 
 COMPLETE RESPONSE: Disappearance of all target lesions; 
malignant nodes <10 mm.  
 PARTIAL RESPONSE: At least 30% reduction in the sum of the 
longest diameter of target lesions, confirmed at 4 weeks.  
 STABLE DISEASE: Neither partial response nor progressive disease 
criteria are met, in a minimum time set by the protocol.  
 PROGRESSIVE DISEASE: At least 20% increase in the sum of the 
diameter, with a minimum absolute increase of 5 mm, taking as reference 
the smallest sum in the study or appearance of new lesions.  
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FOLLOW UP: 
 
 Patients after completion of concurrent chemoradiation were discharged 
from the hospital. Response evaluation was done based on RECIST 
criteria after 4-6 weeks.  
 Chest imaging, hearing evaluation, dental evaluation were done when 
indicated clinically. Continued smoking cessation, counseling to the 
patient and attender, rehabilitation, speech and swallowing therapy.  
 
  
Results and analysis 
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RESULTS AND ANALYSIS 
               The total 60 patients recruited completed their entire treatment 
protocol and all of them were available for analysis of results. 
 PATIENT CHARACTERISTICS:  
AGE DISTRIBUTION:   
             In this study, in both arms most of the patients belonged to the age 
group 51- 60yrs, followed by 41 -50yrs. Around  5% of the patients were in the 
age group of 31-40 years . 
 
Table no: 1, AGE DISTRIBUTION OF THE STUDY POPULATION.  
   ARM    1     ARM   2 
AGE  group NUMBER  % NUMBER   % 
31-40 5 17 % 6 20 % 
41-50 9 30 % 11 37 % 
51-60 16 53 % 13 43 % 
 
 
  
58 
 
 
FIGURE : AGE DISTRIBUTION OF THE STUDY POPULATION 
 
GENDER:  
                      The gender distribution in the study population is dominated by 
the exposure of risk factors like tobacco, alcohol etc. Since male population are 
more frequent for exposure, this study  has  more male patients followed by less 
female patients in both arms.  
 
Table no: 2, GENDER DISTRIBUTION OF THE STUDY POPULATION  
 
 ARM 1 ARM 2 
SEX  PATIENTS  %  PATIENTS % 
MALE  24  80%  25 83 % 
FEMALE  6  20%  5 17 % 
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FIGURE : GENDER DISTRIBUTION OF THE STUDY POPULATION . 
 
 
PERFORMANCE STATUS:  
All patients in this study had a general performance status of  
ECOG (Eastern Cooperative Oncology Group) grade 0 or 1.  
 
Table no:3,   ECOG : PERFORMANCE STATUS 
 ARM 1 
ARM 2 
ECOG  NO.OF PATIENTS  % 
NO.OF 
PATIENTS  
% 
ECOG 0  19 63 %  
18 60 % 
ECOG 1  11 37 %  
12 40 % 
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HABITS:       In the natural history of head and neck cancer, habits 
/addictions of the patients to tobacco, alcohol plays a major role. In this study, 
as expected, majority of the patients had habit of both tobacco (smoking and 
smokeless) and alcohol . 
Table no: 4; HABITS/ADDICTION OF THE STUDY POPULATION  
 
  
 ARM 1 ARM 2 
HABITS  PATIENTS  %  PATIENTS      % 
TOBACCO(SMOKING)  8 27 %  8 27 % 
TOBACCO(SMOKELESS) 7 23 %  8 27 % 
ALCOHOL  6 20 %  5 16 % 
BOTH TOBACCO& 
ALCOHOL 
5  17 %  6 20 % 
NONE 4 13 % 3 10 % 
61 
 
FIGURE ; HABITS/ADDICTION OF THE STUDY POPULATION 
. 
 
Table no: 5, SYMPTOMS AND SIGNS 
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ARM 2 
PRESENTING 
SYMPTOMS/SIGNS  
 
NUMBER  
 
%  
 
NUMBER 
 
% 
PAIN  13  43.3%  
 
14 
   46.6 % 
ULCER/GROWTH  18  60 %  
 
16 
 
53.3 % 
DYSPHAGIA  12  40 %  
13 43.3 % 
ODYNOPHAGIA  8  26.6 %  
7 23.3 % 
NECK SWELLING  9  30 %  
8 26.6 % 
VOICE CHANGE  4 13.3 %  
5 16.6 % 
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FIGURE :  SYMPTOMS AND SIGNS 
 
 
PRIMARY SITE:  
      In this study , arm 1 -Oropharynx were 10 patients, followed by 
Hypopharynx 9 patients  then Oral cavity 6 patients and larynx 5  patients.  Arm 
2 –Oropharynx  were7  patients, followed by Hypopharynx 8 patients then Oral 
cavity 7 patients and larynx 6  patients. 
Table no : 6   PRIMARY GROWTH SITE: 
  ARM 1 ARM 2 
PRIMARY SITE NUMBER % NUMBER % 
ORAL CAVITY 6 20 % 7 23.3 % 
OROPHARYNX 10 33.3 % 9 30 % 
HYPOPHARYNX 9 30 % 8 26.7 % 
LARYNX 5 16.7 % 6 20 % 
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FIGURE : PRIMARY GROWTH 
 
SUBSITE ANALYSIS:  
In the subsite  anaylsis , pyriform sinus were more in number in 
 both arms..  
 
Table no: 7, SUBSITE WISE DISTRIBUTION: 
 
 ARM 1 ARM 2 
SUBSITE NUMBER % NUMBER % 
ANT2/3TONGUE 4 13.3 % 5 16.6 % 
POST 1/3TONGUE 6 20 % 4 13.3 % 
BUCCALMUCOSA 1 3.3 % 1 3.3 %  
RMT 1 3.3 % 1 3.3 %  
TONSIL 4 13.3 % 5 16.6 % 
PYRIFORMSINUS 9 30 % 8 26.6 % 
SUPRAGLOTTIS 5 16.6 %  6 20 % 
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FIGURE : SUBSITE WISE DISTRIBUTION 
 
 
TUMOR STAGE:  
This study included only locally advanced head and neck cancer ,T 
stage with T2 (with node positive), T3, T4a  in both arms. 
   Table :8, TUMOR STAGE  : 
  ARM 1 ARM 2 
TUMOR STAGE NUMBER  % NUMBER % 
 T 1 0 0 0 0 
T 2 8 26.7 % 9 30 % 
T 3 14 46.6 %  14 46.7 % 
T 4a 8 26.7 % 7 23.3 % 
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FIGURE : TUMOR STAGE    
 
 
NODAL STAGE:  Nodal staging 43% of the patients as N1, 37 % of the  
nodes  are  N2 in both arms. 
 
Table no: 9, NODAL STAGE   
 
 ARM 1 ARM 2 
NODAL STAGE NUMBER % NUMBER % 
N 0 6 20 % 6 20 % 
N 1 13 43.3 % 13 43.3 %  
N 2 11 36.7 % 11 36.7 % 
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FIGURE: NODAL STAGE 
 
 
STAGE GROUPING OF THE STUDY SAMPLE:  
 
  The staging grouping was done according to AJCC 7th edition.  
As our general population usually present late to the hospital most of our  
patients were in stage IVA . 
Table no: 10, ARM 1 ,STAGE GROUPING 
 
ARM 1 Tumor nodal 
stage 
T2N1 T2N2 T3N0 T3N1 T3N2 T4aN0 T4aN1 T4aN2 
 
ORAL CAVITY  0 0 1 1 1 1 1 1 
 
OROPHARYNX 2 1 2 2 1 1 1 0 
 
HYPOPHARYNX 1 2 1 1 1 0 1 0 
 
LARYNX 1 1 0 1 1 0 1 0 
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FIGURE :  ARM 1 ,STAGE GROUPING 
 
 
 
 
Table : 11 , ARM 2, STAGE GROUPING 
 
 
ARM 2 Tumor nodal 
stage 
T2N1 T2N2 T3N0 T3N1 T3N2 T4aN0 T4aN1 T4aN2 
ORAL CAVITY  1 1 1 1 0 1 1 1 
 
OROPHARYNX 1 2 1 1 2 0 1 1 
 
HYPOPHARYNX 1 1 2 2 1 0 1 0 
 
LARYNX 1 1 1 1 1 0 1 0 
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FIGURE : ARM 2, STAGE GROUPING 
 
 
 
 
T3N0                                  T4aN0   
T2N1          -STAGE 3       T4aN1                -STAGE 4 a 
T3N1                                  T4aN2             
                                           T2N2 
                                            T3N2 
 
 
Table :12,  STAGE GROUPING 
 
 
 ARM 1 ARM 2 
 
STAGE GROUPING NUMBER % NUMBER % 
STAGE   3 13 43.3 % 15 50 % 
  
STAGE  4a 17 56.7 % 15 50 % 
 
 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
T2N1 T2N2 T3N0 T3N1 T3N2 T4AN0 T4AN1 T4AN2
1 1 1 1
0
1 1 11
2
1 1
2
0
1 11 1
2 2
1
0
1
0
1 1 1 1 1
0
1
0
ORALCAVITY
OROPHARYNX
HYPOPHARYNX
LARYNX
} }
69 
 
FIGURE : STAGE GROUPING 
 
 
 
HISTOLOGICAL DIFFERENTIATION:  
 
  Most of the patients in the study belonged to moderately  
differentiated histology followed by poorly differentiated.  
 
TABLE NO:13, : HISTOLOGIC DIFFERENTIATION 
 ARM 1 ARM 2 
HISTOLOGICAL 
DIFFERENTIATION  
NUMBER  % NUMBER % 
WELL 
DIFFERENTIATED 
6 20% 7  23.33%  
MODERATELY 
DIFFERENTIATED  
18 60% 17  56.66%  
POORLY 
DIFFERENTIATED  
6 20% 6  20%  
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FIGURE : HISTOLOGIC DIFFERENTIATION 
 
 
TREATMENT RESULTS:  
           All 60 patients completed the treatment protocol and were assessed at the 
end of 4-6 weeks. The evaluation was done clinically, which included ENT 
(Ear, Nose, Throat) examination with indirect laryngoscopy and direct 
laryngoscopy, and CT imaging (plain and contrast). The RECIST 1.1 criteria 
were used to classify the response type into a complete response, partial 
response, static or progressive disease. 
 
RESPONSE RESULTS:  
          In this study,80%  had complete response and 20% had partial response in 
arm1 where as 73% of the patients had complete response and 27% had partial 
response in arm2. There was no static response or progression in the study.  
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Table no:14, RESPONSE RESULTS 
    
FIGURE : RESPONSE RESULTS 
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 ARM 1 ARM 2  
RESPONSE  NUMBE
R  
% NUMBER % P value 
COMPLETE RESPONSE  24 80% 22  73.33%  0.52 
PARTIAL RESPONSE  6 20% 8  26.66%  0.60 
STATIC RESPONSE  0 0 0 0  0 
PROGRESSION  0 0 0 0 0 
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 SITE Vs RESPONSE:  
In both arms of this study , Oropharynx had highest complete  
response followed by hypopharynx and larynx and the least was oral cavity. 
 
Table no:16, SITE VERSUS RESPONSE 
   
 
 
 
 
 
 ARM 1 ARM 2 
SITE  COMPLETE  
RESPONSE  
PARTIAL 
RESPONSE  
COMPLETE  
RESPONSE 
PARTIAL 
RESPONSE 
ORALCAVITY         4  (66.6%)      2 (33.3%) 4(57%) 3(42.8%) 
OROPHARYNX       9   (90%) 1(10%) 8(88.8%) 1(11.1%) 
HYPOPHARYNX        7 (77.7%) 2(22.2%) 6(75%) 2(25%) 
LARYNX       4 (80%) 1(20%) 4(66.6%) 2(33.3%) 
73 
 
FIGURE ; SITE VERSUS RESPONSE 
 
SUBSET ANALYSIS:  
All the patient characteristics were analyzed for response at the end 
of the treatment. The subset wise analysis  were done  below. 
Table: 15 , SUBSET ANALYSIS OF RESPONSE 
 
 ARM 1 
 
ARM2 
subsite Complete 
response 
partial 
response 
Complete 
response 
partial 
response 
Ant 2/3 tongue 3 1 3 2 
Post 1/3 tongue 5 1 4 0 
Buccal mucosa 1 0 0 1 
Retromolar 
trigone 
0 1 1 0 
Tonsil 4 0 4 1 
Pyriform sinus 7 2 6 2 
Supraglottis 4 1 4 2 
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FIGURE : SUBSET ANALYSIS OF RESPONSE 
 
  
 
TUMOR STAGE Vs RESPONSE:  
Among T3&T4 lesions,T4 had less complete response than T3 in both  
arms. This shows the advanced nature of the disease. 
 
Table no: 16, TUMOR STAGE Vs RESPONSE 
 ARM 1 ARM 2 
Tumor stage Complete 
response 
Partial 
response 
Complete 
response 
Partial 
response 
T1 0 0 0 0 
T2 8  (100%) 0 8 (88.9%) 1 (11.1%) 
T3 10 (71.4%) 4 (28.6%) 10 (71.4%) 4 (28.6%) 
T4a 6 (75%) 2 (25%) 4 (57.1%) 3 (42.9%) 
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FIGURE : TUMOR STAGE Vs RESPONSE 
  
 
 
NODAL STAGE Vs RESPONSE:  
               All N0 patients had complete response , whereas N2 shows less  
complete response. 
 
 Table no:17, : NODAL STAGE Vs RESPONSE  
  
 ARM 1 ARM 2 
NODAL 
STAGE 
Complete 
response 
Partial 
response 
Complete 
response 
Partial 
response 
N0 6 (100%) 0 6 (100%) 0 
N1 12 (92.3%) 1 (7.7%) 10 (76.9%) 3(23.1%) 
N2 6 (54.6%) 5 (45.4%) 6 (54.6%) 5 (45.4%) 
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FIGURE : NODAL STAGE Vs RESPONSE 
  
 
HISTOLOGICAL DIFFERENTIATION Vs RESPONSE:  
        As already mentioned maximum numbers of the patients in our study were 
moderately differentiated; in which maximum had complete response and less 
had partial response in both arms. All poorly differentiated cancer had complete 
response. In well differentiated tumors , half of them had partial response. 
Table no: 18, HISTOLOGIC DIFFERENTIATION VS RESPONSE 
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HISTOLOGIC 
DIFFERENTIATION  
COMPLETE 
RESPONSE  
PARTIAL 
RESPONSE  
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
WELL 
DIFFERENTIATED  
3 (50%) 3 (50%) 4 (57.1%) 3(42.9%) 
MODERATELY 
DIFFERENTIATED  
15 (83.3%) 3 (16.6%) 11(68.8%) 5(31.2%) 
POORLY 
DIFFERENTIATED  
6 (100%) 0  7(100%) 0 
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FIGURE : HISTOLOGIC DIFFERENTIATION VS RESPONSE 
 
  
 
PERFORMANCE STATUS Vs RESPONSE: 
         The ECOG performance status among the study patients did not  show  
much difference in the response rates, as the study patients are in the ECOG  0 
 or 1.  
 
OTHER FACTORS AFFECTING RESPONSE:  
 
AGE:   In this study ,people  in both arms aged more than 50yrs were around 
 50% ,of which majority showed complete response than younger age group ie, 
 below 40 years.  
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Table no: 19, AGE VS RESPONSE  
                 ARM 1 
 
                  ARM 2 
AGE GROUP COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
31-40Yrs  
 
3 (60 %) 
 
 
2 (40 %) 
 
4 (66.7%) 
 
2 (33.3%) 
41-50Yrs  
 
8 (88.8%) 
 
 
1 (11.2 %) 
 
8 (72.7%) 
 
3 (27.3%) 
51-60Yrs  
 
13 (81.2 %) 
 
 
3 (18.8%) 
 
10 (76.9%) 
 
3 (23.1 %) 
 
  FIGURE: AGE VS RESPONSE 
  
 
GENDER Vs RESPONSE: As the male population dominated the study 75%  
of the males had complete response in contrast to 66% of the females. As the  
male and female ratio was not equivalent it cannot be considered as significant.  
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STAGE Vs RESPONSE:  
         The complete response in Stage IV was around 50 % in both arms  but the  
partial response was  more than 30% which is high compared to Stage III where  
they all had complete response. This is due to the fact that Stage IV disease is  
infiltrative and extensively spreading.  
 
Table no :20, STAGE VS RESPONSE  
        
      ARM 1 
   
                ARM 2 
STAGE  COMPLETE  
RESPONSE  
 
PARTIAL 
RESPONSE  
COMPLETE 
RESPONSE  
PARTIAL 
RESPONSE  
STAGE III   13 (100%) 
 
0 15 (100%) 0 
STAGE IV  11 (64.7%) 
 
6  (35.3%) 7 (46.7%) 8 (53.3 %) 
 
FIGURE: STAGE VS RESPONSE 
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TREATMENT BREAK Vs RESPONSE:  
 
                  Treatment delay due to toxicities which caused prolongation of 
overall treatment time was analyzed for response. There was treatment delay in 
both the arms of around 50 %,  another  50% who proceeded without delay in 
overall treatment time. Among the 50 % of the patients, who  did 1-3 days 
treatment break had more than 75% complete response whereas only around 
50% had complete  response in case of treatment break for 4 days or more in 
both the arms.  
            Though there was treatment break all patient received chemo radiation 
to the prescribed schedule.  
Table no: 21,TREATMENT BREAK VS RESPONSE 
          ARM 1 ARM 2 
Treatment 
break 
number CR PR Number CR PR 
1-3 days  4 3 (75%) 1 (25%) 6 5 (83%) 1 (17%) 
>4 days 7 4 (57%) 3 (43%) 9 5 ( 56%) 4 (44%) 
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FIGURE:  TREATMENT BREAK VS RESPONSE  
 
  
TREATMENT RELATED ACUTE TOXICITIES:  
ACUTE LOCAL TOXICITY: Acute local toxicity is done by RTOG Acute  
morbidity scoring Criteria.  
SKIN REACTION: In this study ,arm 1 -  83 % of the patients had Grade 1 
skin reactions in the form of dry desquamation, decreased sweating. Another 
13% had patchy moist desquamation whereas only 3% of the patient had grade 
3 confluent moist desquamation. Whereas, in arm 2-76 % of the patients had 
Grade 1 skin reactions in the form of dry desquamation, decreased sweating. 
Another 17% had patchy moist desquamation whereas only 6% of the patient 
had grade 3 confluent moist desquamation.  
MUCOSITIS:  As expected there was high incidence of mucositis in this 
study. Nearly 40% of the study population developed grade 2 reactions in the 
form of patchy mucositis which is more in arm 2. Around 13-16% had grade 3 
confluent  mucositis which was more in arm 2 , but there was grade 4 mucositis 
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in 3-6% of the patients which required treatment break and supportive measures 
with analgesics, strict oral hygiene, mouth wash with alcohol free antibacterial 
solution. Also Inj.Dexamethasone 8mg  i.v. bid was given for 4-5 days.  
SALIVARY GLAND /XEROSTOMIA:  
        The salivary gland toxicity in the form of xerostomia is usually managed 
with commercially available artificial salivary agents.In both arms, 73-80% of 
the patients had grade1 xerostomia with complaints like dry mouth and slightly 
altered taste sensation. Some 13-16% patients developed complete dryness, 
sticky saliva as grade 2 toxicity reaction in both arms.  
PHARYNGITIS: 
 The patients with grade 2 and grade 3 dysphagia were given Ryles tube 
feeding and adequate nutrition was maintained. If needed  intravenous fluids 
and parentral nutrition were given.   
LARYNGITIS:  
Grade 2 Laryngitis developed in 46% of the patients in arm 2 who had 
 hoarseness of voice and constant cough requiring cough syrup. Grade 3  
laryngitis developed in 26% of the patients in arm 2 they had only whispered  
speech. Remaining had grade 1 toxicity which subsided on its own. In arm 1,  
the same was present in less number of patients and  less in severity. 
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Table no:22, ACUTE TOXICITY,  ARM 1: 
ACUTE 
TOXICITY  
GRADE 
0  
GRADE  
1  
GRADE  
2  
GRADE  
3  
GRADE 
4  
GRADE 
5  
SKIN 
REACTIONS  
 
0  25(83.3)  4(13.3%)  1 (3.3%)  
 
0  
 
0  
 
MUCOSITIS  
 
0  15(50%) 10(33.3%)  4(13.3%) 1 (3.4%) 
 
0  
SALIVARY 
GLAND  2  24(80%)  4(13.3%)  
 
0  
 
0  
 
0  
PHARYNGITIS/ 
DYSPHAGIA  
 
0  13(43.3%) 9 (30%)  8(26.7%)  
 
0  
 
0  
 
LARYNGITIS  
 
0  16(53.3%) 8(26.7%)  6 (20%)  
 
0  
 
0  
 
Table no:23, ACUTE TOXICITY,  ARM 2: 
ACUTE 
TOXICITY  
GRADE 
0  
GRADE  
1  
GRADE  
2  
GRADE  
3  
GRADE 
4  
GRADE 
5  
SKIN 
REACTIONS  
 
0  23(76.7%)  5(16.6%)  2 (6.7%)  
 
0  
 
0  
 
MUCOSITIS  
 
0  11(36.7%) 12(40%)  5(16.7%)  2 (6.6%) 
 
0  
SALIVARY 
GLAND  2(6.7 23(76.7%)  5(16.6%)  
 
0  
 
0  
 
0  
PHARYNGITIS/ 
DYSPHAGIA  
 
0  8(26.6%)  11(36.7%)  11(36.7%)  
 
0  
 
0  
 
LARYNGITIS  
 
0  8(26.6%)  14(46.7%)  8 (26.7%)  
 
0  
 
0  
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FIGURE : SKIN REACTIONS : 
 
 
FIGURE: MUCOSITIS : 
 
FIGURE:  SALIVARY GLAND TOXICITY: 
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FIGURE:  PHARYNGITIS/ DYSPHAGIA: 
 
 
FIGURE:, LARYNGITIS : 
 
SYSTEMIC TOXICITY:  The treatment related systemic toxicity was  
assessed with CTCAE  V 4.03 and presented . 
NAUSEA: 86% of the study population developed loss of appetite grade1  
nausea during their treatment course in arm 1 where as in arm 2 ,66%.but  
the patient who developed grade 2 nausea was more in arm 2.  
VOMITING:   In arm 2, 80% of the patients had  grade 1(1 or 2 episode) of 
vomiting during chemotherapy mainly Cisplatin. 20% of the patients had grade 
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2(3or4episodes) of vomiting managed by Oral Rehydration Salt and 
Inj.Ondansetron iv bid for 3 -5 days. Intravenous fluids were given whenever 
necessary. In arm 1,only 6% had grade 2 vomiting which was very less than 
arm 2. 
DIARRHOEA:  Only 6% of the patients had grade 1 diarrhoea in both  
arms.Other than that none of the study patients had diarrhea. Mostly the grade  
1 diarrhoea is self-limiting, anti-motility drugs like Tab. Loperamide was used  
when needed.   
 
Table no: 24,  SYSTEMIC TOXICITY ,ARM 1 
TOXICITY  GRADE 1  GRADE 
2  
GRADE 
3  
GRADE 4  
NAUSEA  26 (86.7%)  3 (10%)  1 (3.3%)  0  
VOMITTING  28 (93.3%)  2(6.7%)  0  0  
DIAHORREA  2 (6.66%)  0  0  0  
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FIGURE: , SYSTEMIC TOXICITY ,ARM 1 
 
Table no: 25, SYSTEMIC TOXICITY , ARM 2: 
TOXICITY  GRADE 
1  
GRADE 
2  
GRADE 
3  
GRADE 
4  
NAUSEA  20 
(66.7%)  
8 
(26.7%)  
2 
(6.6%)  
0  
VOMITTING  24 (80%)   6(20%)  0  0  
DIAHORREA  2(6.66%)  0  0  0  
 
FIGURE:, SYSTEMIC TOXICITY ARM 2: 
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HEMATOLOGICAL TOXICITY:  
ANAEMIA:  In this study ,in both arms most of the patients completed their  
treatment without much reduction in their  hemoglobin levels. However around  
10 %  of the patients developed reduction in Hb levels to below 9g% and  
required Packed cell transfusion.  
 
Table no: 26, ANAEMIA 
    ARM 1   ARM 2 
ANEMIA  NUMBER     % NUMBER     % 
GRADE 0   Hb >11 gm 20 66.7 % 18 60%  
GRADE 1   9.5-11 gm 7 23.3 % 8 26.7%  
GRADE 2   7.5-9.5 gm  3 10 % 4 13.3%  
GRADE 3   5-7.5 gm  0 0 0 0  
GRADE 4   < 5 gm 0 0 0 0  
 
FIGURE :, ANAEMIA 
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LEUCOPENIA:   In both arms,majority of patients had WBC count >4000   
completed their treatment without much reduction in WBC count . Only 1 
patient in arm 1 and 2 patient in arm 2 had reduction in WBC count level during 
chemotherapy between 2000 – 3000 grade2 Leucopenia and they were given 
appropriate measures to regain their count and completed the treatment.  
Table :27,LEUCOPENIA  
  ARM 1 ARM 2 
WBC COUNT NO % NO % 
 GRADE 0>4000 26 86.7 % 24 80 % 
GRADE 1    3000-4000 3 10 % 4 13.3 % 
GRADE 2    2000-3000 1 3.3 % 2 6.7 % 
GRADE 3     1000-2000 0 0 0 0 
GRADE 4         <1000 0 0 0 0 
 
FIGURE:,LEUCOPENIA 
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NEUTROPENIA:There was no neutrophil count reduction in the study.  
THROMBOCYTOPENIA:  None of the study patients developed  
thrombocytopenia.  
RENAL TOXICITY:   All patients had normal renal function tests.  
Hence none of the patient developed renal toxicity.  
 
  
Discussion 
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DISCUSSION 
          Squamous cell carcinoma of the head and neck is one of the most 
prevalent cancers in India and has a high social and economic impact. Majority 
of the patients present in the locally advanced stage where surgical resection is 
either not possible or is associated with a lot of morbidity. Historically such 
patients were treated with local RT alone where the local control rates were 
between 50-70% and the 5 year survival was  10-20%.  
There was a definite rationale for the combined use of chemotherapy and 
radiation in locally advanced head and neck cancer. Chemotherapy sensitizes  
tumors  to radiotherapy  by  inhibiting  tumor  repopulation,  it preferentially  
kills the  hypoxic  cells,  inhibiting  the  repair  of sublethal damage caused by 
radiation, it sterilizes the micrometastatic disease outside the radiation fields 
and also decreases the tumor mass which  leads to improved blood supply and 
reoxygenation thus potentiating the effect of radiation.  
Several trials investigating the feasibility as well the improvement of 
outcomes by using chemotherapy along with radiation were performed. In most 
of the trials cisplatin was the mainstay of chemotherapy and it was used alone or 
in combination with some other agents. The expected theoretical advantage of 
adding another cytotoxic agent in the form of chemotherapy to that of radiation 
was clearly demonstrated in these trials and was confirmed by a number of 
meta-analysis.  
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Many meta‑analyses have been conducted to show whether 
chemo‑radiotherapy association is better than radiotherapy alone in view of 
locoregional control or survival.  Among these meta-analyses the most well 
known and important one is the Meta- Analysis on Chemotherapy in Head and 
Neck cancer (MACH-NC) published by Pignon et al. It showed that adding 
chemotherapy to radiation had the following advantages in locally advanced 
cancer of the head and neck: 
1. The use of chemotherapy increased the overall survival at 5 years by 5% 
irrespective of the timing of association 
2. The concurrent use of chemotherapy with radiation improved the overall 
survival by 8% 
3. The use of neoadjuvant chemotherapy followed  by radiation alone is less 
effective as compared to concurrent chemoradiation 
4. The use of cisplatin as the chemotherapy has evident benefit 
5. The use of combination chemotherapy does not seem to provide added 
advantage over the use of single agent. 
6. And as the age of the patient increase over 70, the benefit of adding 
chemotherapy is less evident. 
As of now the standard of care for all those locally advanced unresectable 
head and neck cancer is concurrent chemoradiation with a radiation dose of upto 
70 Gy and three weekly cisplatin of 80-100mg/m2. However the three weekly 
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regimen is associated with a number of toxicities and poor compliance. 
Literature wise evidence exists that the weekly regimen of cisplatin is as 
efficacious as the three weekly regimen as long as a minimum threshold 
cumulative dose of 200mg/m2 is achieved. This comes with a significant lesser 
toxicity in the weekly arm. In a study conducted in our department, the weekly 
regimen was as efficacious as the three weekly regimen with lower toxicities. 
Cisplatin with radiation  Complete response Partial response 
Three weekly 64 36 
weekly 62 38 
 
Theoretically, daily administration of low-dose cisplatin may derive 
the maximum benefit from fractionated administration of concurrent 
chemoradiation. With each fraction of radiation, cisplatin acts as a 
radiosensitiser.  Added to that, pharmacokinetics indicate that increased 
exposure to active platinum compound is more effective i.e. continuous 
exposure , (practically low dose CDDP) is superior to bolus administration 
of chemotherapy.  
The choice of daily cisplatin  instead of weekly schedule was based on 
the experience reported by Jeremic et al and Bartelink et al . 
Jeremic et al  have reported superior outcomes with concurrent use of daily 
cisplatin as compared to RT alone. They observed the benefit appeared to be of 
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the order of the benefit reported by 3 weekly schedule.  It  also highlights on 
practical benefits of such a protocol ie., no need for excess hydration while 
giving low dose daily. This may especially relevant from a tropical countries 
point of view where dehydration is a common occurrence. It also suggests no 
requirement for elective hospitalization for chemotherapy delivery and lastly 
such a schedule offer more control over delivery or stoppage of chemotherapy 
as and  when required. 
Regarding the optimal dose of low dose cisplatin many studies have used 
6 mg/m 2 upto the maximum of10 mg daily. Homma et al  used low dose daily 
cisplatin at 4 mg/m 2 and compared it with weekly carboplatin and found results 
to be inferior. This could have been due to use of ineffectively low dose 
schedule of cisplatin daily. 
Alteration of fractionation by either hyperfractionation or acceleration has 
improved the loco regional control. DAHANCA 6 and 7 was the accelerated 
fractionation schedule followed as standard of care in Denmark. They studied 
two independent risk  factors of radiation resistance known as hypoxia and 
repopulation. The benefit of acceleration was in addition to the effect achieved 
by the use of hypoxic modification. Therefore moderately accelerated RT in 
head and neck cancers with one week reduction in overall treatment time was 
found to be superior to a conventional regimen.  The applicability of this 
protocol has also been tested by International Atomic Energy Agency (IAEA) in 
Asian and African countries. They reported a similar benefit of 10% 
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improvement in local control as the DAHANCA study. In IAEA conducted trial 
significant proportion of patient were treated by a Telecobalt machine. In the 
present study, we too adopted 6 fractions a week radiotherapy using Telecobalt 
machine by reducing the overall treatment time by 1 week. 
Glicksman et al  combined low dose cisplatin with late intensification 
hyperfractionated radiation  in stage III, IV cases. 95% of the patients who 
initiated, completed the treatment.  The disease-specific survival was 78% at 3 
years and the combination was well-tolerated . 
      In the present study ,we compared the overall response rate and 
toxicity occurred while using low dose daily cisplatin as outpatient infusion  
with accelerated radiation versus weekly cisplatin as inpatient infusion  with 
accelerated radiation. 
 In both arms the complete and partial response was 100% with no static 
or progressive disease. Low dose arm shows slightly higher complete response 
ie., 80% compared to weekly arm which shows 73% and the remaining had 
partial response. P value was 0.52 for complete response and 0.60 for partial 
response which was statistically insignificant due to inadequate sample size. 
There was no significant association of the response to therapy when compared 
with the gender of the patient, the age of diagnosis, performance status of the 
patient.  
 In this study, primary tumors in the oropharynx, hypopharynx and the 
larynx had a better response to treatment  in both arms as compared to those in 
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the oral cavity. This may be due to the fact that most of the oral cavity tumors 
were well differentiated and had a poor response to treatment. This also 
corroborated with the finding where poorly differentiated tumors had better 
treatment response rates as compared with the well differentiated histologies. 
 Tumors with lesser volume of disease i.e. T3 diseases had better response 
rates as compared with the T4 diseases which had extensive infiltration  and the 
same findings were seen in the nodal disease where N0 and N1 tumors 
responded better than the N 2 and N3 tumors. Also the response rates in the 
nodal region was better than that in the primary in both arms.  
Also those patients  who had a break in the continuity of the treatment 
had a inferior outcome as compared with those who had no breaks. This reflects 
the importance of completing the treatment without any break as the problem of 
accelerated repopulation can lead to treatment failure. 
                        The primary objective of this study was to determine the 
loco regional control as discussed above.  As the sample size was small, 
statistical analysis is questionable for its significance. 
              The secondary objective of this study is the toxicity assessment. 
Even though all of the patients developed some form of acute toxicity to 
chemoradiation,   the rates of grade 3 and 4 toxicities were low in both arms. 
Around 6% of the patients had grade 3 skin reaction in arm1 and 3% in arm2,P 
value is 0.6 and no grade 4 reactions. Also the rate of grade 4 mucositis were 
also low  in both arms 3% and 6% with P value is 0.7 but it needs  treatment to 
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resolve and again proceeded with complete treatment. This is attributed to the 
additional effect of radiotherapy that too patients are treated with  2D Cobalt 60 
and not in 3DCRT, IMRT. 
                                      The incidence of grade 3 pharyngitis  with P 
value -0.2 were 26% and 36% respectively and the incidence of grade 3 
laryngitis  with P value - 0.5 were 20% and 26% respectively in both arms. 
There were no grade 4 reactions in two arms.  
Other systemic toxicities like nausea (P value-0.4), vomiting (P value-
0.6), diarrhea(Pvalue-0.5) were also seen in the patients but all were manageable 
with routine anti emetic measures.  None of the patients had grade 3 diarrhoea or 
vomiting in both arms. 
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The hematological toxicity was also minimal with no incidence of grade 3 or 4 
toxicity. 10% in arm1 and 13% in arm2  patients had grade 2 anaemia which was 
corrected with blood transfusion. Most of our patients are from low 
socioeconomic status, anemia may be explained due to nutritional deprivation. 
There were 3%  in arm1 and 6% in arm 2 patients had grade 2 leucopenia  and 
managed accordingly. There was no incidence of any febrile neutropenia or 
thrombocytopenia in the patients. 
 All patients were hydrated properly during chemoradiation and thus none of the 
patients had renal toxicity There was no incidence of any liver toxicity in any of 
the patients in both arms.  
  There wasn’t any treatment related deaths in this study. 
MERITS OF THE STUDY:  
 All patients had locally advanced head and neck squamous cell 
caracinoma, the treatment of choice is concurrent chemoradiation 
which was given. 
 Maximum  tumoricidal dose of 70Gy was administrated. 
 Optimal dose of weekly cisplatin > 200mg/m2 and daily cisplatin 
210 mg/m2 were achieved in all patients. 
 The chemotherapy schedule  in both arms assisted to strict regular 
monitoring of toxicity reactions. 
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 Toxicities were manageable. No treatment related death occurred 
in  both arms of this study. Toxicity were graded with RTOG 
Acute radiation morbidity scoring criteria and CTCAE version 4.03 
 Response assessment was done after 4-6weeks of completion of 
chemoradiation,  RECIST 1.1 criteria was used for assessment. 
DEMERITS OF THIS STUDY: 
 There wasn’t long term follow up of this study, so progression free 
survival, overall survival could not be assessed. 
 Radiation delivery was given through 2D technique. 
 This is a phase two trial,  hence randomized control trial must follow to 
determine prognostic significance and survival rates. 
Future perspective:  
This study further established the feasibility and efficacy of concurrent low dose 
Cisplatin  as outpatient  infusion with accelerated radiation in locally advanced 
head and neck cancers. Randomized trial using the same protocol is 
recommended.         
                    
  
Conclusion 
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                              CONCLUSION 
                   The head and neck cancer burden is a distressing problem in the 
developing countries like India. Most of our people are in low socioeconomic 
status, illiterate and lack of awareness of medical attention; makes people to 
present in locally advanced stage. 
 The aim of this study was to evaluate  the response of locoregional 
control and acute toxicity in locally advanced cases  by comparing the low dose 
daily cisplatin  versus weekly cisplatin  concurrently with accelerated radiation. 
The dose of daily cisplatin  6 mg/m2 has shown effective locoregional control 
with a complete response of 80% and partial response of 20% and  the dose of 
weekly cisplatin 40mg/m2 has shown  locoregional control with a complete 
response of 73% and partial response was 27% with slightly higher toxicity  
than low dose which was manageable. This showed that low dose arm was not 
inferior to weekly arm. 
 Though there is lack of long term follow up of this study, locoregional 
control was effective. Large scale randomized study are recommended in near 
future for Progression free survival and Overall Survival. 
       In our institution  which  are overburdened with patients , low dose 
cisplatin with accelerated radiation schedule appears feasible and logistically 
suitable out-patient  option with good locoregional control  and with 
manageable   toxicity in locally advanced head and neck cancer.  
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RTOG ACUTE RADIATION MORBIDITY CRITERIA 
SITE   GRADE 0  GRADE1  GRADE2  GRADE3   GRADE 4  
SKIN  No 
change 
over 
baseline   
Follicular, faint 
or dull erythema/ 
epilation/dry 
desquamation/ 
decreased  
sweating   
 
Tender or 
bright 
erythema, 
patchy moist 
desquamatio 
n/ moderate  
edema   
 
Confluent, 
moist 
desquamati 
on other than 
skin folds,  
pitting edema  
Ulceration, 
hemorrhage,  
necrosis   
 
Mucous 
Membrane  
 
No change 
over  
baseline   
 
Injection/ may 
experience mild  
pain not 
requiring  
analgesic   
 
Patchy 
mucositis 
which may 
produce an  
inflammator 
y 
serosanguinit 
is discharge/ 
may 
experience 
moderate 
pain requiring 
analgesia   
 
Confluent 
fibrinous 
mucositis/ may 
include severe 
pain requiring  
narcotic   
 
Ulceration, 
hemorrhage 
or necrosis   
 
SALIVARY  
GLAND   
 
No change 
over  
baseline   
 
Mild mouth 
dryness/ slightly 
thickened 
saliva/ may have 
slightly altered 
taste such as 
metallic taste/ 
these changes 
not reflected in 
alteration in 
baseline feeding 
behavior, such 
as increased use 
of liquids with 
meals  
Moderate to 
complete 
dryness/ 
thick, sticky 
saliva/  
markedly  
altered taste   
 
 Acute 
salivary 
gland  
necrosis   
 
Pharynx  
& 
Esophagu 
s   
No change 
over  
baseline   
 
Mild dysphagia 
or odynophagia/ 
may require 
topical 
anesthetic or 
non-narcotic 
analgesics/ may  
require soft diet   
 
Moderate 
dysphagia or 
odynophagia 
/ may require 
narcotic 
analgesics/ 
may require 
puree or  
liquid diet   
 
Severe 
dysphagia or 
odynophagia 
with 
dehydration or 
weight 
loss(>15% 
from 
pretreatment 
baseline) 
requiring   
N-G feeding 
tube, I.V. 
fluids or hyper  
alimentation   
 
 
Complete 
obstruction, 
ulceration, 
perforation,  
fistula   
 
Laryngitis   
 
No change 
over  
baseline   
 
Mild or 
intermittent 
hoarseness/cou 
gh not requiring 
antitussive/ 
erythema of  
mucosa   
 
Persistent 
hoarseness 
but able to 
vocalize/ 
referred ear 
pain, sore 
throat, 
patchy 
fibrinous 
exudate or 
mild 
arytenoid 
edema not 
requiring 
narcotic/  
antitussive   
 
Whispered 
speech, throat 
pain or 
referred ear 
pain requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid  
edema   
 
Marked 
dyspnea,  
stridor or 
hemoptysis 
with 
tracheosto 
my or 
intubation 
necessary   
 
 
 
 
HEMATOLOGIC TOXICITY  
Grade  0  1  2  3  4  
HEMATOLOGIC  
WBC (X 1000)   
 
>=4.0   
 
3.0 - <4.0  
 
2.0 - <3.0   
 
1.0 - <2.0   
 
<1.0   
PLATELETS   
(X 1000)   
 
>=100   
 
75 - <100   
 
50 - <75   
 
25 - <50   
 
<25 or 
spontaneous 
bleeding   
NEUTROPHILS   
 
>=1.9   
 
1.5 - <1.9   
 
1.0 - <1.5   
 
0.5 - <1.0   
 
<0.5 or 
sepsis   
 
HEMOGLOBIN  
(GM %)   
>11  
 
11-9.5   
 
<9.5 - 7.5   
 
<7.5 - 5.0   
 
-  
 
 
 
APPENDIX  
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS  
CTCAE VERSION 4 
GRADE  1  2  3  4  
Nausea   Loss of appetite 
without 
alteration in 
eating habits   
 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration or 
malnutrition   
 
Inadequate oral 
caloric or fluid 
intake, tube feeding, 
TPN, or 
hospitalization 
indicated   
 
-  
Vomiting   
 
 1-2  
episodes  
(separated 
by 5  
minutes) in  
 24 hrs  
3-5 
episodes 
(separated 
by 5 
minutes) in  
24 hrs  
>/=6 episodes 
(separated by 5 
minutes) in 24 hrs, 
tube feeding, TPN or 
hospitalization 
indicated   
 
Life 
threatening 
consequences, 
urgent 
intervention 
indicated   
 
Diarrhea  Increase of <4 
stools per day 
over baseline; 
mild increase in  
ostomy 
output 
compared to 
baseline  
Increase of 4 6 
stools per day 
over baseline; 
moderate 
increase in 
ostomy output 
compared to 
baseline  
Increase of =7 
stools per day over 
baseline; 
incontinence; 
hospitalization 
indicated; severe 
increase in ostomy 
output compared to 
baseline; limiting 
self care ADL  
Life 
threatening 
consequences; 
urgent 
intervention 
indicated  
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INFORMATION TO PARTICIPANTS 
Title :Comparison of low-dose daily cisplatin versus weekly cisplatin  along 
with concurrent accelerated radiotherapy in locally advanced head & neck 
cancer 
Name of Participant: 
Name of the Principal(co – investigator) :DR.V. AMUTHA 
Name of the institution : Department of radiotherapy, RGGGH, MMC. 
You are invited to take part in this research/ study/procedures/tests. The 
information in this document is meant to help you decide whether or not to take part. 
Please feel free to ask if you have any queries or concerns. 
What is the purpose of research? 
65% patients with head and neck tumors present with locally advanced  disease. 
Concurrent chemoradiotherapy is a treatment program for locoregionally advanced 
squamous cell carcinomas of the head and neck (SCCHN), with established 
benefits in both organ preservation and survival. Accelerated radiation means 
Reduction in overall treatment time  by increasing the weekly number of fractions 
decreases the opportunity for tumor cell regeneration during treatment and 
therefore, increases the probability of tumor control for a given total dose.  
daily administration of low‑dose cisplatin may derive maximum benefit from 
fractionated administration of both treatment modalities concurrently. With each 
fraction of RT, cisplatin acts as a radiosensitizer 
  Weekly cisplatin is a more acceptable regimen than three weekly cisplatin. 
 Radiotherapy will be delivered by opposing lateral fields with a telecobalt 
machine using Thermoplastic immobilization devicein the form of 
Phase I  to include the primary and the draining lymph node regions and a 
dose of 44 Gy/22 fractions/4.5 weeks was delivered 5 days in a week at 2 
Gy/fraction (Monday to Friday). 
 In phase II-off-cord reduction to be done, and a dose of 16 Gy/8 
fractions/1.5 weeks at 2 Gy/fraction was delivered  5 days in a week 
(Monday to Friday).  
Phase III will be delivered as a boost on Saturday, as limited volume portal 
including original GTV with a margin of 2 cm. A dose of 10 Gy/five 
fractions/over five Saturdays at 2 Gy/fraction was delivered. 
 Weekly Cisplatin arm: 
           CDDP (35 mg/m2) weekly (maximum 50 mg) along with proper 
premedication will be  given. 
 
     Daily cisplatin arm: 
           CDDP will be  given at 6 mg/m2 (capped at 10 mg) in 500 ml normal 
saline (NS) solution for all 6 weeks of treatment. 
injectionondansetron 8 mg will be  given just before chemotherapy 
       Entire treatment is to be completed in 6 weeks time .Primary and gross 
adenopathy receive70 Gy.  
 We want to test the efficacy and safety of “Accelerated radiotherapy with 
weekly chemotherapy or low dose daily chemotherapy “ .We have obtained 
permission from the Institutional Ethics Committee.  
The study design:   double arm prospective study 
Study Procedures: 
The study involves evaluation of Locally advanced squamous cell carcinoma of the 
head and neck with accelerated radiotherapy and chemo in the form of  
weeklyinj.cisplatin or low dose daily cisplatin. Every week before chemotherapy, 
the study physician will examine you. Some [blood / urine /clinical examination 
other] tests will be carried out at each visit. [… … ml of blood will be collected at 
each visit. Blood collection involves prick with a needle and syringe.] These tests 
are essential to monitor your condition, and to assess the safety and efficacy of the 
treatment given to you. 
In addition, if you notice any physical or mental change(s), you must contact the 
persons listed at the end of the document.  
You may have to come to the hospital (study site) for examination and 
investigations apart from your scheduled visits, if required.  
Possible benefits to other people  
The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, Institutional Ethics Committee 
and any person or agency required by law like the Drug Controller General of 
India to view your data, if required. 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken 
care of and you will not lose any benefits to which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving 
any reasons. However, it is advisable that you talk to the research team prior to 
stopping the treatment/discontinuing of procedures etc. 
 
Signature of Investigator                                                                      Signature of  
Participant  Date 
 
 
 INFORMED  CONSENT   FORM 
TITLE OF THE STUDY:Comparison of low-dose daily cisplatin versus weekly 
cisplatin  along with concurrent accelerated radiotherapy in locally advanced 
head & neck cancer 
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPAL ( Co – Investigator ) : DR.V.AMUTHA 
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
 
_____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. 
I am over 18 years of age and, exercising myfree power of choice, hereby give my 
consent to be included as a participant in” :Comparison of low-dose daily 
cisplatin versus weekly cisplatin  using concurrently  with six fractions per 
week radiotherapy in locally advanced head & neck cancer”. 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past 12 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms.  
8. I have not participated in any research study within the past  12month(s). 
9. I agree to under go complete blood count, renal and liver function test, chest x 
ray, CT scan   of the head and  neck 
10. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
11. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. 
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are 
publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document 
 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name ________________ Signature_________________ Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ Date________________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent 
Name ________________ Signature_________________ Date________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 கதி᾽ᾪᾲᾆ சிகிᾲைச அளிᾰகபᾌΆ இடᾷதிᾤ῀ள ேதா᾿ பராமாிᾺᾗ 
ெசᾼ ெசᾼயாேத  
 சிகிᾲைச அளிᾰகᾺபᾌΆ  ᾙᾸைதய 
நா῀ ம᾵ᾌΆ ᾙகᾲசவரΆ 
ெசᾼயலாΆ.  
 
 சிகிᾲைசயிᾹ ேபாேதா ,சிகிᾲைச 
இைடெவளியிᾹ  ேபாேதா 
(சனி,ஞாயிᾠ) ᾙகᾲசவரΆ 
ெசᾼயᾰᾂடாᾐ.  
 ேதா᾿ உாிᾹதேலா சிவᾸதாேலா 
மᾞᾷᾐவைர அᾎக ேவᾶᾌΆ. 
 சிகிᾲைச கிைடᾰᾁΆ இடᾷதி᾿ 
 தᾶணீேரா விய᾽ைவேயா 
படᾰᾂடாᾐ. 
 அதᾹ ேம᾿ ேதᾱகாᾼ 
எᾶெணᾼ,வாசᾢᾹ ,ᾙகபᾫட᾽, 
மᾴச῀  தடவᾂடᾐ . 
 ᾐணி ைவᾷᾐ ேதாைல 
ேதᾰகᾰᾂடாᾐ. 
 வாᾼ பராமாிᾺᾗ 
 மᾞᾷᾐவ᾽ ᾂறிய அளவி᾿ 
சைமய᾿ உᾺᾗ மιᾠΆ ஆᾺப 
ேசாடா உᾺᾗ ஆகியவιைற 
தᾶணீாி᾿ கலᾸᾐ நாᾤ -ஆᾠ 
ᾙைற வாைய ெகாபளிᾰக 
ேவᾶᾌΆ . 
 ᾁழᾸைதக῀ பிரῃ ெகாᾶᾌ ப᾿ 
ᾐலᾰகலாΆ . 
 மᾞᾷᾐவ᾽ ᾂறிய மᾞᾸைத ம᾵ᾌΆ 
உபேயாகிᾰகᾫΆ . 
 
 
 அதிக அளᾫ ெவயிேலா ᾁளிேரா 
அதᾹ ேம᾿ படᾰᾂடாᾐ.  
 
ெசᾼ                                                                              
  அதிக காரΆ எᾶெணᾼ 
 ேச᾽ᾰகᾂடாᾐ (ஊᾠகாᾼ) 
 ᾋ காபி தவி᾽ᾰகᾫΆ. 
 
 ᾗைக பிᾊᾰகᾰᾂடாᾐ, மᾐ 
அᾞᾸதᾰᾂடாᾐ . 
 
 ஆᾺபி᾿ வாைழ பழΆ சிறிய 
ᾐᾶᾌகளாகேவா பழᾲசரகேவா 
ᾁᾊᾰகலாΆ.  
 தினΆ ஒᾞ ேவகைவᾷத ᾙ᾵ைட 
சாᾺபிடலாΆ. 
 ேவக வாᾼᾷத காᾼகறிகைள 
ம᾵ᾌΆ சாᾺபிᾌᾱக῀ . 
 
 சிᾺῄ மிᾲச᾽ காரேசῂ 
ேபாᾹறவιைற தவி᾽ᾰகᾫΆ. 
 
 பழᾱகளி᾿ திரா᾵ைச ,எᾤமிᾲைச 
தᾰகாளி தவி᾽ᾰகᾫΆ.  
 தினΆ இரᾶᾌ கᾺ பா᾿ (ᾘῄ᾵ 
ஹா᾽ᾢᾰῄ )ᾁᾊᾰகᾫΆ. 
 ேவக ைவᾷத ᾐவரΆ பᾞᾺᾗ,பாசி 
பயᾠ ,ᾆᾶட᾿, உᾞைள கிழᾱᾁ 
சாᾺபிடலாΆ . 
 பாᾢ᾿ ேதாᾼᾷத 
ெரா᾵ᾊᾐᾶᾌக῀  சாᾺபிடலாΆ . 
 எளிதி᾿ ஜீரணΆ ஆகᾰᾂᾊய 
உணைவ ம᾵ᾌΆ சாᾺபிᾌᾱக῀ . 
 காᾼகறி ᾇᾺ ,ம᾵டᾹ,சிᾰகᾹ ᾇᾺ 
ᾁᾊᾰகலாΆ .  
 ெவιறிைல பாᾰᾁ ᾚᾰᾁᾺெபாᾊ 
பாᾹபராᾰ, ஹாᾹῄ ,மாவா 
கᾶᾊᾺபாக பயᾹ 
பᾌᾷதᾰᾂடாᾐ . 
 
 
 
